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1. INTRODUCTION 
Bone-related diseases, such as osteoporosis, affect hundreds of millions of people worldwide 
and pose a tremendous burden to health care [1]. Osteoporosis, characterized by enhanced 
bone resorption, leads to reduced bone mass and increased risk of fractures. Furthermore, it is 
a disease of rapidly increasing prevalence and high morbidity. Thus, increased awareness of 
this condition on the part of the medical community and the public has led to an increase in 
screening measures to make the diagnosis and in improvements in its treatment. Therefore, 
newer therapeutic approaches based on a better understanding of the pathophysiology of 
osteoporosis are needed [1]. 
Bone is constantly being remodeled. This is the natural, healthy state of continuous uptake of 
old bone (resorption) followed by the deposit of new bone (formation). The cells that form 
new bone are called osteoblasts and the cells responsible for resorption of old bone are called 
osteoclasts. Osteoporosis occurs as a result of a mismatch between osteoclasts and osteoblasts 
activities. The result is a thinning of the bone with an accompanying loss in bone strength and 
a greater risk of fracture. Although many acquired or environmental factors are known to 
affect the adult bone mineral density [2], genetic factors are also known to play a major role 
[3]. Understanding the mechanisms that control the remodelling process and its regulation 
will clarify not only the local control of the function of bone cells but also the 
pathophysiology of accelerated bone loss in osteoporosis.  
One of the most significant advances in bone biology in the past decade has been the 
identification of receptor activator of nuclear factor-kappa B (RANK) and its ligand 
(RANKL) as key regulators of bone remodelling. RANKL, a member of the tumor necrosis 
factor superfamily, is secreted by osteoblasts in response to a variety of hormonal and 
cytokine signals known to be important for bone metabolism and is the principal regulator of 
the differentiation and activity of osteoclasts. RANKL signalling is mediated by its receptor 
RANK on osteoclasts; the binding of RANKL to RANK is inhibited by sequestration to a 
soluble decoy receptor, osteoprotegerin (OPG). OPG is co-secreted by osteoblasts and serves 
to modulate the effective levels of RANKL. As expected, animal models confirm that 
RANKL-excess shifts that balance of bone metabolism in the direction of catabolism and 
causes osteoporosis. Conversely that absence of RANKL increases bone density. Therefore, 
RANKL inhibition offers the therapeutic possibility to treat osteoporosis. 
The successful development of transgenic animal models for human diseases has led to 
remarkable impacts on the diagnosis, treatment and intervention in human diseases. 
Furthermore, they have helped to clarify our understanding of disease pathophysiology. 
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Unfortunately, many mouse disease models often do not reflect the relevant human conditions 
sufficiently. Pigs however show similarities in size, physiology, organ development and 
course of disease. Therefore, they represent an important and ideal mammalian model for 
human biology research.  
Taken together, the main aim of this doctoral thesis is: Establishment of an osteoporotic large 
animal model by regulated over-expression of extracellular domain of porcine Receptor 
Activator of NF-КB Ligand (sRANKL). In order to accomplish the main aim, the following 
project goals were defined: 
1.  Cloning and stable over-expression of the porcine soluble RANKL protein in swine cells.  
2.  Characterization of osteoclast formation in porcine system. 
3.  Investigation of the effects of porcine sRANKL over-expression on osteoclast formation. 
4.  Establishment of an inducible Tet-On-psRANKL system in vitro. 
5.  Generation of transgenic pigs over-expressing porcine sRANKL upon induction. 
6. Characterization of transgenic piglets and re-cloning of the best expressing one. 
7. In vivo induction of psRANKL expression to study osteoporotic markers. 
This study is a part of the DFG research group “Mechanisms of fracture healing and bone 
regeneration in osteoporosis” (DFG 793/project 2). It established the first transgenic large 
animal model for osteoporosis, which can be used to study fracture healing.  
 
1.1 OSTEOPOROSIS 
1.1.1 Definition and risk factors 
Osteoporosis is a chronic bone disorder characterized by reduced bone mass and alteration of 
bone architecture (Figure 1.1), resulting in increased bone fragility and fracture risk [4]. 
Although there are no current practical methods to assess overall bone strength, bone mineral 
density (BMD) correlates closely with skeletal load bearing capacity and fracture risk [5]. The 
World Health Organization (WHO), therefore, defines osteoporosis in humans as a BMD 
based on the T-score. T-score is the difference between the patient’s BMD and the mean 
BMD of a young adult reference population. Based on T-score, four different variations exist: 
healthy (a T-score of –1.0 or higher), osteopenia (a T-score of less than –1.0 but higher than –
2.5), osteoporosis (a T-score of –2.5 or less) and severe osteoporosis (a T-score of –2.5 or less 
with a fragility fracture) [6]. 
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Figure 1.1.: Comparison of bone architecture from healthy (A) and osteoporotic patient (B). From [4] 
 
Although age is a common cause associated with bone fracture, there are several other 
important secondary causes of osteoporosis. Other pathogenetic factors include reduced 
physical activity, vitamin D insufficiency, genetic factors, sex hormone status, nutrition, 
smoking, alcohol excess, low weight, low muscle mass, corticosteroid use, Caucasian or 
Asian race, family history of fragility fracture, heparin, hypogonadism, thyrotoxicosis, 
deficiency of calcium, gender, geographical region, bone quality, primary or secondary 
amenorrhea, caffeine intake and rheumatoid arthritis [7-14]. 
 
1.1.2 Forms of osteoporosis 
Osteoporosis can be classified as primary or secondary. The primary osteoporosis is a 
multifactorial illness including genetic alterations, hormonal changes and a sedentary lifestyle 
and it is mainly seen in elderly people [15]. Postmenopausal osteoporosis, the most common 
primary form of osteoporosis, is often observed in trauma units dealing with fracture 
treatment. Secondary forms of osteoporosis are predominantly medication/drug-induced 
forms, such as glucocorticoid-induced osteoporosis. Secondary osteoporosis can be observed 
in both young and old people [16]. 
 
1.1.3 Clinical aspects of osteoporosis 
The bone strength primary reflects the integration of bone density and quality. Bone density is 
expressed as grams of minerals per area or volume. While bone quality is defined as the 
architecture, turnover, damage accumulation and mineralization of the bone [17]. When a 
failure-inducing force, such as trauma, is applied to an osteoporotic bone, a fracture occurs, 
thus osteoporosis is a significant risk factor for fractures. These fractures are a major cause of 
morbidity and mortality in the elderly people. Screening for individual fracture risk is still not 
reliable in usual clinical settings. The following factors have to be taken into account in order 
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to estimate the progression of the disease: bone architecture and geometry, mineralization, 
microdamage accumulation and properties of the collagen and mineral matrix [18]. 
Furthermore, there is a clear relationship between aging and the incidence of osteoporosis. 
Women are also affected more often than man, due to the postmenopausal estrogen deficiency 
[16,19].  
 
1.1.4 Osteoporosis treatment 
Treatment for osteoporosis requires a multidisciplinary approach encompassing patient 
information, lifestyle advice, physical measures, pharmacological therapy and in some cases 
interventional options. The choice of treatment is influenced by factors such as bone mineral 
density, stage of disease progression, nature and site of fracture, patient age, underlying co-
morbidities and side effects. The goal of treatment of osteoporosis is the prevention of bone 
fractures by reducing bone loss or by increasing bone density and strength [20]. 
Currently, the most effective medications for osteoporosis that are approved by the Food and 
Drug Administration (FDA) are antiresorptive agents bisphosphonates, which decrease the 
removal of calcium from bones and inhibit resorption [21]. Bisphosphonates such as 
alendronate (Fosamax®), risedronate (Actonel®), raloxifene (Evista®), ibandronate 
(Bonviva®) and the recently approved zoledronate (Zometa®) are the examples of 
antiresorptive agents [22]. Furthermore, a newly approved medication by FDA for use in 
postmenopausal women with risk of osteoporosis is an inhibitory antibody against RANKL, 
Denosumab (Prolia®) which increases bone mineral density, decreases bone resorption and 
prevents fractures [23,24]. Calcium and vitamin D supplements should be co-prescribed with 
other treatments for osteoporosis. A daily intake of elemental calcium (1 200 mg per day) and 
vitamin D3 (800–1 000 IU per day) are considered to be necessary for prevention of 
osteoporosis [25]. 
 
1.1.5 Biochemical markers of osteoporosis 
The field of bone turnover markers has developed considerably in the past decade. 
Biochemical monitoring of bone metabolism depends upon measurement of enzymes and 
proteins released during bone formation and resorption. Various biochemical markers are now 
available, although these markers are not recommended for use in diagnosis of osteoporosis, 
they appear to be useful for the individual monitoring of osteoporotic patients [26]. A 
summary of bone formation markers is as follows: serum total alkaline phosphatases, serum 
bone–specific alkaline phosphatases, serum osteocalcin and serum type 1 procollagen C-
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terminal/N-terminal (C1NP or P1NP) and a summary of bone resorption markers is the 
following: urinary hydroxyproline, urinary total pyridinoline (PYD), urinary free 
deoxypyridinoline (DPD), urinary collagen type 1 cross-linked N-telopeptide (NTX), urinary 
or serum collagen type 1 cross-linked C-telopeptide (CTX), bone sialoprotein (BSP) and 
tartrate-resistant acid phosphatase 5b (TRACP5b) [27].  
Diagnosis of osteoporosis is not based on evaluation of bone markers, rather the BMD 
assessment is still the criterion standard for evaluation and diagnosis [28]. The level of bone 
mass can be assessed with adequate precision by measuring BMD using dual-energy x-ray 
absorptiometry (DEXA) [29]. However, this measurement does not capture all risk factors for 
fracture. BMD assessment with DEXA is a surrogate marker of treatment efficacy that has 
been widely used in clinical trials. However, mean values for markers of bone turnover are 
higher in osteoporosis patients than in the matched controls [30]. 
Such markers can also be useful in selected cases to improve the assessment of individual 
fracture risk when BMD measurement by itself does not provide a clear answer. The 
combined use of BMD measurement and bone markers is likely to improve the assessment of 
the risk of fractures in bone disorders [27,31,32]. 
 
1.1.6 The health economics of osteoporosis 
Fractures due to osteoporosis and osteoporosis itself do not only have a major impact on 
peoples’ health and quality of life, but they also place an enormous economic burden on 
healthcare systems in Europe and worldwide. As the population demographics change, an 
increased number of osteoporotic fractures are expected. A growth that may in some societies 
be compounded by a rise in age-specific incidence. Thus, osteoporosis potentially could 
increase to epidemic proportions within 50 years. Driven by this, there is a marked increase in 
research into the pathogenesis of bone loss and a heightened interest in developing new 
therapeutic agents to prevent and treat the disease [33].  
According to the World Health Organization report from 1994, about 30% of postmenopausal 
women are estimated to have osteoporosis [6]. The prevalence rate of osteoporosis ranges 
between 13% and 30% for the US and the UK [33-35]. The prevalence in Germany is 
estimated to be between 4 million and 7 million people [36-38]. One out of three 
postmenopausal women and one out of five men over the age of 50 years will experience 
osteoporotic fractures [39]. The report of the European Commission from 1998 estimates an 
increase in the incidence of hip fractures in Germany until the year 2040, from 117 000 in 
2000 to 240 000 in 2040 [40]. As the median age of the German population increases, the 
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costs associated with osteoporotic fractures are also likely to increase. Thus, the osteoporosis 
is responsible for millions of fractures annually and total medical care costs in Europe, 
including hospitalization and rehabilitation. These were 76,7 billion € in 2005 [41].  
Due to its social and economic implications, osteoporosis is a major public health problem. 
Osteoporosis-related fractures account for more hospital days per year than diabetes, 
myocardial infarction or breast cancer [39,42,43]. Therefore, it is essential to identify 
individuals at high risk and take preventive measures in order to reduce the costs associated 
with osteoporosis. Furthermore, the osteoporosis issue demonstrates the need for effective 
prevention and treatment strategies [39]. 
 
1.2 BONE REMODELLING 
During the normal homeostasis of bone, formation and resorption are balanced so when old 
bone is resorbed by osteoclasts, a similar amount of new bone is formed by osteoblasts. The 
purpose of remodelling is to regulate calcium homeostasis, repair micro-damaged bones and 
to shape and sculpture the skeleton during growth. During osteoporosis there is an 
abnormality in the remodelling process of bone in which bone resorption exceeds bone 
formation, thus leading to a net loss of bone. 
Bone remodelling occurs in focal and particular units called basic multicellular units (BMU) 
where osteoblasts and osteoclasts are coupled together via paracrine cell signalling [44]. Their 
action is controlled by a number of chemical factors, which either promote or inhibit the 
activity of the bone remodelling cells. This process consists of five phases: (1) initiation: 
preosteoclasts are stimulated and differentiate under the influence of cytokines and growth 
factors into mature active osteoclasts; (2) resorption: osteoclasts digest the mineral matrix; (3) 
reversal phase: end of resorption; (4) formation: osteoblasts synthesize a new bone matrix; 
and (5) quiescence: osteoblasts become resting bone lining cells on the newly formed bone 
surface (Figure 1.2). 
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Figure 1.2.: Remodelling of bone in a bone multicellular unit starts with osteoblastic activation of osteoclast 
differentiation, fusion and activation (A, B). When resorption lacunae are formed, the osteoclast leaves the area, 
and mononucleated cells of uncertain origin appear and “clean up” the organic matrix remnants left by the 
osteoclast, also possibly forming the cementum line (dotted line) at the bottom of the lacunae (C). During the 
resorption process, coupling factors are released from the bone extracellular matrix and these growth factors 
contribute to the recruitment and activation of osteoblasts to the resorption lacunae (D). The osteoblasts will then 
fill the lacunae with new bone and when the same amount of bone is formed as that being resorbed, the 
remodelling process is finished and the mineralized extracellular matrix will be covered by osteoid and a one-
cell layer of osteoblasts (E). From [4]. 
 
1.2.1 Cells involved in bone remodelling 
As mention above, the cells responsible for bone remodelling are osteoblasts, which secrete 
new bone and osteoclasts, which break bone down (Figure 1.3). The structure of bones 
requires close cooperation between these two cell types. 
Osteoblasts are mononuclear cells of mesenchymal origin involved in the bone formation. 
They produce and secrete the major part of the organic bone matrix in a well-regulated 
process to form mineralized bone [45]. Osteoblasts are postproliferative and cuboidal cells 
lining the bone matrix at sites of active bone production. Osteoblasts can also be recognized 
by their ability to synthesize a number of phenotype-specific bone matrix macromolecules 
such as osteocalcin, bone sialoprotein, osteopontin, alkaline phosphatase, proteoglycans, 
certain hormone receptors, cytokines and growth factors [46].  
Osteoclasts, first named by Kölliker [47], are multinucleated cells from hematopoietic origin; 
more specifically from cells in the monocytes-macrophage linage [48,49]. Osteoclasts are the 
only cells known to be responsible for bone resorption. They are localized on bone surfaces 
and have a phagocytic-like mechanism similar to circulating macrophages [50]. 
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Figure 1.3.: Bone remodelling cells (osteoblasts and osteoclast), support cells (osteocytes and bone lining cells), 
nonmineral matrix of collagen, noncollagenous proteins (osteoid) and inorganic mineral salts deposited within 
the matrix. From www.iofbonehealth.org. 
 
1.2.2 Cellular mechanism of bone resorption 
Morphology of the osteoclast 
An osteoclast is a large cell that is 40 mm in diameter. They contain 15-20 oval closely 
packed nuclei and are found in pits on the bone surface, which are called Howship´s lacunae. 
Osteoclasts are characterized by a cytoplasm with a homogeneous foamy appearance, which 
is due to a high concentration of vesicles and vacuoles (Figure 1.4). These vacuoles are 
lysosomes filled with acid phosphatase [51]. At a site of active bone resorption, the osteoclast 
forms a specialized cell membrane, the "ruffled border (RB)," that touches the surface of the 
bone tissue [52]. 
 
Figure 1.4.: Schematic illustration of a bone resorbing osteoclast. Modified from [52]. 
 
Osteoclast formation 
Osteoclast differentiation has various characteristic features such as multinucleation, induced 
by the cell fusion of mononuclear osteoclasts; synthesis of the vacuolar proton pump and 
acids to dissolve the bone mineral; formation of ruffled borders, to secret protons and acids; 
formation of a sealing zone, to prevent proton and acid leakage [53]. 
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The differentiation of osteoclast precursors into mature multinucleated osteoclasts requires 
different factors including hormonal and local stimuli [54]. As first noted in 1990, osteoblastic 
or bone marrow stromal cells are also required for osteoclast differentiation [55]. These 
accessory cells express the two molecules that are essential and sufficient to promote 
osteoclastogenesis: the macrophage colony-stimulating factor (M-CSF) [55-57] and the 
receptor for activation of nuclear factor kappa B ligand (RANKL) (also known as OPGL, 
ODF and TRANCE) [48,55,58-63].  
By a process that requires cell-to-cell contact, RANKL will activate its cognate receptor 
RANK, on osteoclast progenitor cells. Together with the activation of the receptor c-Fms by 
M-CSF, which is imperative for macrophage maturation, this will lead to an expansion of the 
osteoclast progenitor pool, an increased survival of these cells and the initiation of a 
differentiation program which terminates in fusion of the mononucleated progenitor cells and 
the development of the osteoclasts. Finally, these osteoclasts become activated to bone-
resorbing osteoclasts. Osteoblasts also secrete a protein that strongly inhibits osteoclast 
formation called osteoprotegerin (OPG). It acts as a decoy receptor for the RANKL, thus 
inhibiting the true connection between osteoclasts and osteoblasts via RANK and RANKL 
(Figure 1.5). It is the balance between the expression of RANKL and OPG which dictates the 
quantity of bone resorbtion [64]. Moreover, complete osteoclastogenesis can now be achieved 
in vitro with pure populations of macrophages, which are exposed only to M-CSF and 
RANKL [58]. 
 
Figure 1.5.: A schematic overview of the RANKL/RANK/OPG system. RANKL mediates a signal for 
osteoclast formation through RANK expressed on osteoclast progenitors. OPG counteracts this effect by 
competing for and neutralizing RANKL. Modified from [62]. 
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Osteoclastic resorption 
Bone resorption by osteoclasts is a multistep process, which is initiated by the proliferation of 
immature osteoclast precursors and finished by the degradation of the organic and inorganic 
phases of bone by the mature resorptive cells. 
The initial event in bone degradation is the attachment of osteoclasts to the target matrix [65]. 
A number of cell surface glycoproteins have been identified as intercellular adhesion 
molecules. These have been classified into three major molecular families; the 
immunoglobulin (Ig) superfamily, the integrin superfamily and the cadherin family [66-70].  
Once attached to the bone, the cell generates an isolated extracellular microenvironment 
between itself and the bone surface [71] in the sealing zone. This microenvironment, rich in 
filamentous actin (F-actin) and largely devoid of organelles, is organized as a ring 
surrounding the ruffled membrane [52]. The F-actin in the sealing zone localizes itself within 
the plasma membrane protrusions, known as podosomes [72]. 
Both the mineral and organic components of the bone matrix are degraded by osteoclasts 
within the resorption lacunae underneath ruffled border membranes [66]. The inorganic bone 
matrix is dissolved by the acidic environment, revealing the organic collagen network. 
Carbonic anhydrase II (CA-II) is a cytoplasmic enzyme hydrolyzing carbon dioxide into 
bicarbonate and protons [73-75]. CA-II is suggested to be the main source of protons for the 
acidification of the resorption lacuna [76-78]. A vacuolar-type proton pump, V-ATPase, is 
present in high amounts within the membranes of a population of intracellular vesicles. V-
ATPase transports the protons generated by CA-II into these vesicles, which are then 
transported and fused to the ruffled border membrane [76-80] releasing their proton content to 
the lacuna. Acidification of the extracellular resorption lacuna is completed by passive, 
potential-driven chloride transport [81]. The result of these ion transporting events is a 
secretion of HCl into the resorptive microenvironment, prompting a pH of 4.5 [71]. This 
acidic milieu first mobilizes bone minerals; subsequently, the demineralized organic 
component of the bone is degraded by a lysosomal protease, Cathepsin K [82]. When the 
osteoclast stops resorption and moves away from the resorption lacuna, phagocytes clean up 
the remains and make room for osteoblasts to begin bone formation in the newly formed 
resorption cavity [83].  
Only recently it has been shown that osteoclasts remove the degradation products of the bone 
matrix from the resorption lacuna by transcytosis [84,85]. The degradation products, both 
organic and inorganic, are endocytosed to the resorbing osteoclast, transported through the 
cell in large vesicles and finally released into the extracellular space. The bone-specific 
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enzyme TRACP is located in cytoplasmic vesicles, which fuse to the transcytotic vesicles and 
participate in destroying the endocytosed material in the transcytotic route [86]. 
 
Basic characteristic of RANKL, RANK and OPG and their roles in bone metabolism 
The identification of the factors involved in osteoclast development began with OPG [59,87]. 
OPG (Figure 1.6C) is a member of the tumor necrosis factor receptor (TNFR) superfamily 
and is highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, 
small intestine, thyroid, lymph node, trachea, adrenal gland, testis and bone marrow [88]. 
Molecular binding experiments showed that OPG associates with RANKL and functions as a 
decoy receptor [62]. The expression of OPG is directly or indirectly modulated by a large 
number of factors; including TNF-α, interleukins, sex steroids, growth hormone, IGF-1, the 
macrophage colony stimulating factor, thyroid, parathyroid hormones, vitamin D and 
lipoproteins [89-92].  
The receptor for RANKL is RANK (Figure 1.6A), a type I transmembrane protein originally 
cloned from dendritic cells [93]. Although OPG functions as a dimer, RANK, like other 
members of the tumor necrosis factor receptor (TNFR) superfamily, assembles into functional 
trimers [88]. RANK is ubiquitously expressed in skeletal muscle, thymus, liver, colon, small 
intestine, adrenal gland, osteoclast, mammary gland epithelial cells, prostate and pancreas 
[93-96].  
Four groups independently cloned RANKL (Figure 1.6B) as an apoptosis regulatory gene, a 
ligand for RANK and a binding partner of OPG [61,62,93,95]. The RANKL gene gives rise to 
splice variants that encode two forms of type II transmembrane proteins and one form of a 
secreted protein [97]. Although a high RANKL expression can be found in lymph nodes, 
thymus and lung: only low levels of RANKL can be detected in spleen, bone marrow, 
peripheral blood, leukocytes, heart, placenta, skeletal muscle, stomach and the thyroid 
[61,62,93-95]. In addition, RANKL expression is induced in mammary gland epithelial cells 
in pregnancy [96], activated T-cells [93,98,99] and malignant tumor cells [100]. 
1a,25(OH)2D3, parathyroid hormone, TNF-α, IL-1 and IL-11 promote RANKL synthesis 
[101]. Increased RANKL expression has been defined in a wide variety of conditions 
characterized by osteolysis: osteoporosis, malignant bone disease (especially myeloma), 
Paget’s disease and rheumatoid arthritis [102]. 
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Figure 1.6.: Diagrammatic representations of RANK (A), RANKL (B) and OPG (C). From [103]. 
 
The biological roles of these factors in bone metabolism have been studied by the analysis of 
gene knock out and transgenic mice. OPG-deficient mice show severe osteoporosis 
accompanied by increased osteoclast differentiation and activation [104,105]. In contrast, 
transgenic mice over-expressing rat OPG show osteopetrosis associated with a decrease of 
osteoclasts [87]. RANKL- and RANK-deficient mice show the typical osteopetrosis, defective 
tooth eruption and lacking osteoclasts, but they retain the normal osteoclast progenitors 
[87,98,106,107]. Over-expression of RANKL in transgenic mice induces severe osteoporosis 
[104]. In line with mouse models, mutations in RANK and OPG have been identified in 
patients with bone disorders [108].  
 
1.3 GENE TRANSFER TECHNOLOGIES 
Gene transfer is the process of introducing foreign DNA into host cells aiming to affect the 
expression of the protein of interest. The gene transfer can occur in vitro in the cell culture or 
in vivo in living organisms.  
An ideal gene delivery method needs to meet 3 major criteria: it should protect the transgene 
against degradation by nucleases in intercellular matrices, it should bring the transgene across 
the plasma membrane and into the nucleus of target cells and it should have no detrimental 
effects on the transgene expression [109]. 
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Many different methods of gene delivery have been developed for various types of cells and 
tissues, from bacterial to mammalian. Generally, the methods can be divided into two 
categories, viral and non-viral [110]. Virus mediated gene delivery utilizes the ability of a 
virus to inject its DNA or RNA inside a host cell. A gene that is intended for delivery is 
packaged into a viral particle [111]. Non-viral methods include physical and chemical 
methods. All of these methods have advantages and disadvantages depending on the purpose 
of the study. Selection of an appropriate gene transfer vector requires careful consideration of 
a number of factors, including: duration of protein expression required for efficacy (transient 
versus long term), target cells (ease of transduction, receptor expression, dividing versus non-
dividing), route of gene delivery (ex vivo versus in vivo), maximum threshold of vector-
induced immune response acceptable for the host and desired temporal regulation of 
transgene expression (inducible versus constitutive) [112]. A wide variety of viral and non-
viral systems have been investigated for their utility as gene delivery vehicles. It is unlikely 
that one vector technology will be ubiquitously appropriate for all scenarios, so vehicles 
should be optimized for the specific indications [113].  
 
1.3.1. Viral methods of gene transfer 
Viruses are parasitic particles, which are capable of efficiently infecting host cells with 
genetic sequences. This property has been exploited to develop recombinant viral vectors as 
delivery vehicles, capable of prolonged transgene expression and markedly higher 
transduction efficiency. In general, the viral genome is based on DNA or RNA, encased in a 
protein capsid and in some cases surrounded by a phospholipid bilayer [112]. Viruses are 
typically rendered replication-incompetent by deletion of a significant portion of the genetic 
sequence essential for viral propagation and replacement of this sequence with a transgene 
expression cassette [112]. All viruses bind to their hosts and introduce their genetic material 
into the host cell as part of their replication cycle. Viral vectors are able to mediate gene 
transfer with high efficiency and the possibility of long-term gene expression. The acute 
immune response, immunogenicity and insertion mutagenesis have raised serious safety 
concerns about some commonly used viral vectors [114]. The limitation in the size of the 
transgene that recombinant viruses can carry and issues related to the production of viral 
vectors present additional practical challenges [114]. 
Numerous viral vectors with divergent properties have been studied for gene transfer, the 
most common include; retrovirus, adenovirus, adeno-associated virus and lentivirus [113]. 
 
1. Introduction                                                                                                                            20 
 
Lentiviral vectors 
Lentiviruses, such as human immunodeficiency virus type 1 (HIV-1), are a specialized class 
of retrovirus, which are capable of infecting non-dividing cells. The ability of these vectors to 
transduce macrophages, hematopoietic stem cells, neurons and hepatocytes with high 
efficiency has prompted an increased interest in the use of this technology for gene transfer 
[115-117]. Although the integration sites of lentiviral vector are significantly more limited 
than other retroviral family classes [118], this feature markedly decreases the risk of oncogene 
activation. Additionally, these vectors carry safety risks associated with their pathogenic HIV 
origin and the possibility that recombination events could lead to replication-competent 
viruses [119].  
 
1.3.2. Nonviral methods of gene transfer 
Nonviral vectors typically consist of plasmid DNA alone or in combination with a carrier (e.g. 
liposomes, cationic polymers and porous scaffolds) that is non-specifically taken up by cells 
through endogenous endocytic mechanisms [120].  
Methods of nonviral gene delivery have also been explored using physical (carrier-free gene 
delivery) and chemical approaches (synthetic vector-based gene delivery). Physical 
approaches, including needle injection [121], electroporation [122], gene gun [123,124], 
ultrasound [125] and hydrodynamic delivery [126,127], employ a physical force that 
permeates the cell membrane and facilitates intracellular gene transfer. The chemical 
approaches [128,129] use synthetic or naturally occurring compounds as carriers to deliver the 
transgene into cells.  
Non-viral methods present certain advantages over viral methods, with simple large-scale 
production and low host immunogenicity. Conventional systems are limited by low 
transfection efficiency, transient expression and non-selective cell targeting. Despite these 
limitations, nonviral vectors are easy to manufacture, able to incorporate large sequences of 
DNA and are cost-effective [130].  
Although significant progress has been made in the basic science and applications of various 
nonviral gene delivery systems, the majority of nonviral approaches are still much less 
efficient than viral vectors, especially for in vivo gene delivery. 
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1.4 TRANSGENESIS OF LARGE ANIMALS 
Transgenesis is the process of introducing an exogenous gene (transgene) into a living 
organism. Finally, that organism will exhibit a new property and transmit that property to its 
offspring. Transgenesis can be facilitated by gene transfer methods mentioned above.  
The production of transgenic animals is a powerful tool used successfully in many animal 
systems to study early embryogenesis, organogenesis and adult tissues [131]. It is a 
particularly important technique for studying gene function and disease models like 
osteoporosis.  
 
1.4.1 Nuclear transfer 
Nuclear transfer (NT) is a delicate process which represents a major hurdle in the 
development of cloning technology [132].  
In NT the nucleus, which contains the organism's DNA of a somatic cell is removed and the 
rest of the cell discarded. At the same time, the nucleus of an egg cell is removed. The nucleus 
of the somatic cell is then inserted into the enucleated egg cell. After being inserted into the 
egg, the somatic cell nucleus is reprogrammed by the host cell. The egg, now containing the 
nucleus of a somatic cell, is stimulated with a shock and will begin to divide (Figure 1.7) 
[133]. 
 
Figure 1.7.: (A) Enucleation of the oocyte at metaphase II; (B) Selection of donor cell; (C) Injection of donor 
cell into the perivitelline space. (D) Donor cell attached to the enucleated oocyte. From [133]. 
 
In order to begin the development process, the membranes separating the ooplast and the 
donor nucleus must be fused. This can be accomplished in two ways: (1) by the 
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administration of a brief electrical pulse, or (2) by chemical fusion. The fusion process also 
stimulates the embryonic development, which, if successful, results in the development of 
blastocysts that are transplanted into surrogate mothers [134]. After NT of a fully 
differentiated donor cell into a cytoplast, the resulting reconstruct can develop into an embryo 
and even a viable animal.  
Offsprings have been obtained from an ever-growing list of species [135]. Nuclear transfer in 
mammals was not achieved until over three decades after the initial reports of Briggs and 
King on the production of adult frog clones using embryonic nuclei [132]. During the late 
1980s and early 1990s, success in mammalian NT was limited mainly to domestic livestock 
(sheep, cattle). During this time period embryonic blastomeres, primarily from morula-staged 
embryos, were used as nuclear donors.  At that time, embryonic blastomere NT did not work 
with mice [135].  
 
1.4.2. Embryo transfer 
Embryo transfer (ET) refers to a step in the process of in vitro fertilization whereby one or 
several embryos are placed into the uterus of the surrogate mother with the intent to establish 
a pregnancy. 
After a NT, the developing clone is transferred at the blastocyst stage into a surrogate mother 
in whom the estrous cycle has been synchronized. After transfer of the embryo clone(s), the 
pregnancy is allowed to proceed normally; no additional hormones or special treatments are 
required to establish or maintain pregnancy. The surrogate mother is often chosen to be 
distinctively different from the donor animal with respect to some clearly visible trait [136].  
 
1.4.3 Transgenic pigs 
Since the birth of the first cloned sheep, more than 10 animal species have been cloned by 
somatic cell nuclear transfer [137]. The need for application of new embryo technologies in 
pig breeding is moderate when compared with other domestic species. Pigs have short 
reproductive cycles and large litters, so traditional breeding combined with artificial 
insemination offers the possibility for rapid genetic advancement [138]. Additionally, in 
contrast with traditional laboratory animals, pigs have a relatively long lifespan and their 
organ size, anatomy and physiology are similar to humans. Therefore, pigs can be studied and 
treated with methods and instruments that are used in human medicine. Pig organs may also 
be considered for xenotransplantation to replace diseased human organs temporarily or even 
permanently [139,140].  
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To produce transgenic pigs, the most promising past and present approaches, i.e. 
intracytoplasmic sperm injection (ICSI), pronuclear microinjection, somatic cell nuclear 
transfer (SCNT) and in vitro maturated oocytes as recipients are based on a reliable and 
efficient embryology background (Figure 1.8) [141].  
The first piglet born after nuclear transfer was created using blastomeres of 4-cell stage 
embryos as donors [142].  
 
Figure 1.8.: Efficient production of transgenic pigs by using somatic cell nuclear transfer. An expression vector 
carrying a removable selection cassette is transfected into nuclear donor cells. After selection, the resulting 
transgenic cells are pooled and used for nuclear transfer. Pooling of cell colonies reduces the time in culture and 
allows the generation of independent founder fetuses/offspring in one litter. Cloned embryos are transferred to 
synchronized recipients. Depending on the expected onset and tissue specificity of transgene expression, 
pregnancies may be terminated to recover fetuses, or birth and early development of offspring is awaited. 
Fetuses or tissues from born offspring are processed for transgene integration and expression studies, while 
individual cell cultures are established for re-cloning of the fetuses/offspring with the most suitable 
integration/expression pattern. From [143]. 
 
1.5 INDUCIBLE TRANSGENE Tet SYSTEM 
The unregulated over-expression of some proteins risks aberrant effects of uncontrolled cell 
signalling, including tumorigenesis [144,145] and protein over-production [146,147]. 
Inducible expression systems have been developed to address these concerns and to control 
the activity of genetically engineered cells [148]. These systems typically drive the transgene 
expression from inducible promoters, which are regulated by engineered and/or non-
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mammalian transcription factors. The activity of these transcription factors is controlled by 
exogenous chemical agents, which permit (“ON” state) or repress (“OFF” state) the transgene 
expression. 
The most widely characterized of these systems is the tetracycline inducible expression 
system, first described by Gossen and Bujard [149]. The original system utilizes the 
tetracycline-controlled transactivator (tTA), which is a fusion of the Tet repressor (TetR, 
found in Escherichia coli) and a VP16 activation domain (produced by the Herpes Simplex 
Virus). Gene expression is activated as a result of the binding of tTA to tetracycline response 
elements (TREs) located within an inducible promoter. In the absence of tetracycline (Tc), 
tTA binds the tet operon and activates the transcription of the downstream gene of interest. 
However, in the presence of tetracycline, the antibiotic binds to tTA, blocks the binding to the 
tet operon and subsequently transactivates it in a dose-dependent manner (Figure 1.9). The 
 
Figure 1.9.: The tetracycline system for mammalian transgenesis. Two expression cassettes need to be delivered 
to the target cell. One expresses the tTA/rtTA protein, which either binds to Tc analogue Doxycycline (Doxy) or 
the tet operator (tetO7) and the other expresses the therapeutic gene under the control of tetO7. Gene expression 
is conditional on the binding of tTA/rtTA to tetO7 and hence on the absence of tetracycline. (A) Fusion of TetR 
to Herpes simplex VP16 yields a strong transcriptional activator tTA, whose activity can be switched off in the 
presence of the Doxycycline; (B) A mutant form of tTA, rtTA, however, which fails to act as a transactivator in 
the absence of Doxy, becomes active in the presence of Doxy and leads to transgene expression as a result of 
administration of Doxy. 
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tetracycline response element consists of 7 repeats of the 19 bp bacterial tet sequence 
separated by the spacer sequences. The TRE is usually placed upstream of a minimal 
promoter that has very low basal expression in the absence of bound Tet-Off (or Tet-On). 
This system is compatible in vitro by adding tetracycline to the cell culture media and in vivo 
by delivering a Tc via the drinking water. This Tet-Off version was later modified to a Tet-On 
system, in which transactivation increases with tetracycline concentration [150]. Despite the 
greater clinical relevance of the Tet-On derivative, the Tet-Off system is widely reported as 
having a greater degree of inducibility, including lower expression levels in the “OFF” state 
and higher expression levels in the “ON” state [151]. However, recent modifications of the 
Tet-On system have shown improved induction levels and lower basal activity in the “OFF” 
state [152,153]. 
The Tet system has advantages over other (like Cre, FRT and estrogen receptor) conditional 
gene expression systems. In the Tet system, the activation of the knock out of the gene is 
reversible once recombination is accomplished. The Tet system has very tight control on the 
expression. However, the Tet system, which depends on transcription and subsequent 
translation of a target gene, is not as fast-acting, which stabilizes the already-expressed target 
protein upon hormone administration [153]. 
 
1.6 PIGS AS MODEL ORGANISMS 
It has been widely believed that pigs were first domesticated from the wild boars (Sus scrofa) 
approximately 9 000 years ago. Domestication, selective breeding and adaptation to diverse 
environments have led to the development of more than 250 breeds worldwide.  
The pig is evolutionarily distinct from the primates and rodents [154]. An initial evolutionary 
analysis and the available human and mouse genome data revealed that for each of the types 
of orthologous sequences investigated, the pig is closer to humans than mice [140]. The 
genome of the pig comprises 18 autosomes, with X and Y sex chromosomes. The pig genome 
is of similar complexity, genetic information and size as the human genome and is estimated 
at 2.7 Gbp. In 1993, the public databases had only gathered approximately 600 pig sequences. 
In 2009 there were 1,850 working draft sequences from the pig genome that have been 
released to the public domain. In April 2011, the Swine Genome Sequencing Consortium 
released a mixed assembly of the whole porcine genome [155]. 
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1.6.1 Pigs in human medical research 
Livestock pig breeds and miniature pigs are relevant models in many fields of medical 
research [156]. The omnivores, human and pig, have a large number of similarities in 
anatomy, physiology, metabolism and pathology, e.g., they have a very similar 
gastrointestinal anatomy and function, the size of organs, pancreas morphology and metabolic 
regulation [143]. Pigs and other farm animals have been proposed as models to study human 
diseases, including non-insulin dependent diabetes, cancer and neurodegenerative disorders, 
because these require longer observation periods than those possible in mice [157]. The pig 
has also evolved as the major target species for producing xenografts to overcome the 
growing gap between demand and availability of appropriate human organs [157].  
With regard to bone anatomy, morphology, healing and remodelling, the pig bone is 
considered to be closely representative of human one. While having a denser trabecular 
network, the pig has a human like lamellar bone structure. Furthermore, pigs have a similar 
rate of bone regeneration, cortical bone mineralization [158] and a close bone remodelling 
rates to humans [159]. Nevertheless, up to now no truly satisfying large animal model for 
osteoporosis exists [159]. 
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2. MATERIALS AND METHODS 
 
2.1 CELL BIOLOGY 
2.1.1 Eukaryotic cells 
The 293FT (HEK293FT) (Supplementary figure 1A) cell line was purchased from Invitrogen 
(Karlsruhe, Germany) and is a derive from primary embryonic human kidney 293F cell line 
transformed with human adenovirus type 5 DNA [160] which stably expresses the SV40 large 
T antigen. They have epithelial-like cell morphology and are growing in a monolayer. The 
293FT cells are suitable host for generating lentiviral constructs [117] and are generally 
amenable to transfection using standard method. In addition, these cells have a Neomycin 
resistance and, therefore, should be maintained in medium containing Geneticin (Invitrogen).  
Primary porcine fetal fibroblast (pFF) (Supplementary figure 1B), porcine ear fibroblast (pEF) 
(Supplementary figure 1C) and porcine kidney cell (pKC) (Supplementary figure 1D) were 
isolated using collagenase treatment by Annegret Wünsch at the Institute of Molecular 
Animal Breeding and Biotechnology (LMU, Prof. Eckhard Wolf). The pFFs and pEFs exhibit 
typical fibroblast-like morphology, i.e. spindle shaped (bipolar) or stellate (multipolar), while 
the pKCs contain a mixed population of cells with fibroblast-like and epithelial-like 
morphology. All cell types grow as adherent monolayer and were isolated from Swabian-Hall 
breed swine. Precisely, pFF-psRANKL and pFF-rtTA-psRANKL were isolated from a 27 and 
40 days old fetus, respectively, while pEF-TRE-psRANKL and pKC-rtTA were isolated from 
a 1-28 days old newborn piglet form ear or kidney, respectively.  
Porcine osteoclast precursor cells (Supplementary figure 1E) were isolated from bone marrow 
of German Landrace swine, which was withdrawn from the posterior iliac crest of the pelvic 
bone and centrifuged by density gradient method (see 2.8.1). 
All cells are assayed and tested negative for HIV-1, hepatitis-B & C (human cells), 
mycoplasma, bacteria, yeast and fungi (human and porcine cells).  
 
2.1.2 Media  
Media for 293FT cells 
293FT cells were maintained in complete growth media composed of Dulbecco's Modified 
Eagle Medium (D-MEM (high glucose, +Glutamine, +Pyruvate), PAA, Pasching, Austria) 
supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich, Munich, Germany), 0.1 
mM MEM Non-Essential Amino Acids (NEAA, Invitrogen), 1% Penicillin-Streptomycin 
solution (Pen-Strep, 100×, PAA), 2 mM L-glutamine (PAA) and 500 g/ml Geneticin 
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(Invitrogen). Cells were preserved in freezing media composed of 90% complete growth 
media + 10% Dimethylsulfoxid (DMSO, Merck, Darmstadt, Germany). 
 
Media for primary porcine cells 
Complete growth media for porcine cells was composed of D-MEM (high glucose, 
+Glutamine, +Pyruvate, PAA) supplemented with 10% FBS (Sigma-Aldrich), 0.1 mM NEAA 
(Invitrogen), 1% Pen-Strep (PAA), 1mM Sodium pyruvate (Sigma-Aldrich), 1 mM L-
Glutamine (PAA) and 0.1 mM 2-mercaptoethanol (Sigma-Aldrich). For the rtTA or/and TRE-
psRANKL-expressing cells, a 2% Tet System Approved Fetal Bovine Serum (Clontech, 
Saint-Germain-en-Laye, France) was used as supplement in culture media. For genetically 
modified cells during selection process, media used was composed of complete growth media 
supplemented with 10 µg/ml Blasticidin (PAA) for psRANKL-transgenic or 400 µg/ml 
Geneticin (Invitrogen) for rtTA-transgenic cells, respectively. Cells were preserved in 
freezing media composed of 90% FBS + 10% DMSO. 
 
Media for porcine osteoclast precursor cells 
Complete growth media for porcine osteoclast was composed of α-MEM-Glutamax 
(Invitrogen) supplemented with 10% FBS (Sigma-Aldrich), 1% Pen-Strep (PAA), 20 ng/ml 
human soluble RANK-ligand (hsRANKL, PeproTech, Hamburg, Germany) and 5 ng/ml 
human macrophage-colony stimulating factor (M-CSF, Sigma-Aldrich). 
 
 2.1.3 Eukaryotic cell culture 
Standard sterile cell culture plastic ware was purchased from Sarstedt (Nümbrecht, Germany). 
Cell culture vessels (Nunc, Langenselbold, Germany) used in this study were T-25, T-75 and 
T-225 cell culture flasks and 6-well culture dish. Sterile condition was maintained all along 
and cells were incubated at 37°C in a humidified 5% CO2 incubator (Jouan, Thermo 
Scientific, Bremen, Germany). 
 
Passaging 
Upon reaching confluency (see Cell culture conditions) all medium was removed from the 
flask and the cells were washed once with phosphate buffered saline (PBS, PAA) to remove 
excess medium and serum. 1× Trypsin/EDTA solution (PAA) was added for maximum 5 
minutes or until all cells are detached. The detached cells were washed off and resuspend in 
media.  
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A small portion of the cell suspension was taken to calculate cell density. In an eppendorf 
tube, cell suspension and trypan blue stain solution (Invitrogen) were mixed in 1:2 ratio. The 
trypan blue staining was used to determinate cell viability. 10 µl of this suspension was 
pipetted to the Neubauer cell counting chamber (Brand, Germany), the chamber was placed 
under the phase contrast microscope and the counting was performed. Cells viability should 
be at least 95% for healthy log-phase cultures. After the counting, a defined number of cells 
were seeded (for T-25 flask 125 000, for T-75 flask 375 000, for T-225 flask 1 125 000 and 
for 6-well dish 48 000 cells) or cryopreserved. 
 
Freezing 
For cryopreservation, a specific freezing media was prepared for each cell type (see 2.1.2). 
After cell trypsinization and counting (see Passaging), the cells were pelleted by 
centrifugation for 5 min at 500 g at room temperature. The supernatant was completely 
aspirated and the cell pellet was resuspend in pre-cooled to 4°C freezing media. Next, the cell 
suspensions were aliquoted in pre-labelled cryovials, which were then placed on dry ice and 
finally stored in liquid nitrogen tank. 
 
Thawing 
Cells were stored in liquid nitrogen and were thawed quickly in a 37°C water bath. 
Subsequently, the cells were transferred to a flask containing prewarmed, complete growth 
medium. The cells were incubated overnight at 37°C for allowing the cells to attach to the 
bottom of the flask. The next day, the medium was aspirated and replaced with fresh, 
complete medium. 
 
Cell culture conditions 
The human cell culture was performed according to the manufacturer’s recommendations. 
293FT cells were used for virus production and transfection and were cultured to maximum 
20th passage. The confluence of the monolayer before passaging was approx 90-95%. The 
media was exchange every third day and the cells were splitted in 1:8 ratio.  
The primary porcine cells were used for over-expression experiments and generation of 
transgenic piglets and were cultured to maximum 10th passage in a 0,02% collagen (SERVA 
Electrophoresis GmbH, Heidelberg, Germany) coated vessels. The confluence of the 
monolayer was 95-100% and media was change every second day. The splitting ratio was 1:3. 
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The osteoclast precursor cells were used for generation of the osteoclasts. The cells were not 
passaged and media was change every 4 days.  
Wild type and genetically modified porcine cells were continuously passaged, observed and 
photographed under phase contrast microscope (Axiovert S100, Carl Zeiss, Jena, Germany) to 
check and document the morphology of cells.  
 
Stimulation with Doxycycline 
To induce psRANKL under the control of TRE promoter, a 1 µg/ml Doxycycline (Clontech) 
was added into cell culture. Cells were harvested after 3 days of Doxycycline stimulation. 
 
2.1.4 Bacterial strains 
For plasmid cloning and propagation, 2 type of E. coli competent cell were used:  
• One Shot TOP10 Competent Cells (Invitrogen), which are derivates from DH10B E. 
coli strain. They provide high cloning efficiency and plasmid propagation and are 
ideal for high-copy number plasmids amplification. 
• One Shot Stbl3 Chemically Competent Cells (Invitrogen) which are HB101 E. coli 
strain derivate, recommended for use with unstable inserts such as lentiviral DNA.  
 
2.1.5 Bacterial culture media 
The LB (Luria-Bertani) media (10% Bacto Tryptone, 10% NaCl and 5% Bacto Yeast extract) 
was adapted from [161]. All components of the media were mixed, autoclaved and 
immediately used or preserved at 4°C.  
S.O.C. (Super Optimal broth with Catabolite repression) media (2% Bacto Tryptone, 0,5% 
Bacto Yeast extract, 0,2% 5M NaCl, 0,25% 1M KCl, 1% 1M MgCl2, 1% 1M MgSO4 and 2% 
1M glucose) was purchased from Invitrogen and stored at 4°C. 
For preparation of hard selective media, 15% agar was added to the LB media. After 
sterilization, the media was cooled to RT and depending on the plasmid resistance antibiotics, 
100 µg/ml of Ampicillin (ROTH, Karlsruhe, Germany) or 50 µg/ml of Kanamycin (ROTH), 
were added. Media was then mixed by gentle shaking and poured into 10 cm bacterial Petri 
dishes (Greiner BioOne, Frickenhausen, Germany). The obtained LB-agar plates were stored 
at 4°C. 
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2.2 CLONING OF EXTRACELLULAR DOMAIN OF PORCINE RANKL 
cDNA 
To isolate the extracellular domain of porcine RANKL cDNA, the oligonucleotide primers 
were designed based on the published human cDNA sequence (Supplementary table 1). Total 
RNA was isolated from pig osteoblast as a source for RNA and the reverse-transcription 
polymerase chain reaction (RT-PCR) products at the predicted size of about 700 base pairs 
(bp) were gel-purified (see 2.3.3) and cloned into the pCR2.1-TOPO cloning vector 
(Invitrogen). Next, to obtain secreted form of the pRANKL, the psRANKL cDNA from 
pCR2.1-TOPO plasmid was subcloned into the pSecTag ABC plasmid (Invitrogen) by sticky 
end BamHI/NotI ligation and sequenced (Sequiserve, Vaterstetten, Germany).  
 
2.3 CLONING OF PLASMIDS 
2.3.1 Plasmids and their cloning 
pCR2.1-TOPO vector (Invitrogen) (Supplementary figure 2A) is designed for the cloning of 
PCR products directly from a PCR reaction. The vector include 3´-T overhangs for direct 
ligation of non-proofreading Taq-amplified PCR products, T7 promoter for in vitro RNA 
transcription and sequencing, M13 forward and reverse primer sites for sequencing, EcoRI 
sites flanking the PCR product insertion site for easy excision of inserts, Kanamycin and 
Ampicilin resistance genes for selection in E. coli, easy blue/white colony screening for 
selection of recombinants. 
 
pSecTag2ABC (Invitrogen) (Supplementary figure 2B) is a mammalian expression vector 
designed for the secretion, purification and detection of fusion proteins. The vector has a large 
multiple cloning sites in three reading frames to simplify cloning in frame with the N-terminal 
secretion signal. The vector offer the following features: secretion signal from the V-J2-C 
region of the mouse Ig kappa-chain for efficient secretion of recombinant proteins, 
cytomegalovirus (CMV) promoter for high-level constitutive expression, C-terminal 
polyhistidine (6xHis) tag for rapid purification with nickel-chelating resin and detection with 
an anti-His (C-term) antibody, C-terminal c-myc epitope for detection with an anti-myc 
antibody, bovine growth hormone (BGH) polyadenylation signal and transcription 
termination sequence to enhance mRNA stability, SV40 origin for episomal replication and 
simple vector rescue in cell lines expressing the large T antigen, Zeocin resistance gene for 
cost-effective selection in mammalian cells. 
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pENTR11 (Invitrogen) (Supplementary figure 2C) is a pUC-based plasmid allowing cloning 
DNA sequences using restriction endonucleases and ligase to create a Gateway entry clone. 
The resulting entry clone is ready for recombination with a destination vector to create an 
expression clone. It contains attL1 and attL2 sites for site-specific recombination of the entry 
clone with a Gateway destination vector to ensure cloning of the gene of interest in the correct 
orientation for expression, Kozak consensus sequence for efficient translation initiation in 
eukaryotic systems, ribosome binding site for efficient translation initiation in prokaryotic 
systems, rrnB transcription termination sequences to prevent basal expression of the PCR 
product of interest in E. coli, pUC origin for high-copy replication and maintenance of the 
plasmid in E. coli, Kanamycin resistance gene for selection in E. coli, the 
ccdB⁄Chloramphenicol fusion gene located between the two attL sites for counterselection.  
 
pLenti6/V5-DEST (Invitrogen) (Supplementary figure 2D) is a pUC-based plasmid used for 
production of pseudotype lentivirus for effective transduction of dividing and non-dividing 
mammalian cells. The vector provides a stable and long-term expression of DNA sequence 
into the host cells. It include a multiple biosafety features such as psi packaging signal for 
viral packaging [162], HIV Rev response element for Rev-dependent nuclear export of 
unspliced viral mRNA [163] and U3 elements. The vector contains Rous Sarcoma Virus 
enhancer/promoter for Tat-independent production of viral mRNA in the producer cell line 
[163], modified HIV-1 5′ and 3′ Long Terminal Repeats for viral packaging and reverse 
transcription of the viral mRNA [164], CMV promoter for constitutive expression of the gene 
of interest from a viral promoter, two recombination sites, attR1 and attR2, Chloramphenicol 
resistance gene for counterscreening, the ccdB gene for negative selection, C-terminal V5 
epitope for detection of the recombinant protein of interest [165], SV40 promoter driving 
expression of Blasticidin, Blasticidin [166,167] resistance gene for selection in E. coli and 
mammalian cells, Ampicillin resistance gene for selection in E. coli and pUC origin for high-
copy replication of the plasmid in E. coli 
 
pTet-On (Clontech) (Supplementary figure 2E) express the reverse tet-responsive 
transcriptional activator (rtTA) from the strong immediate early promoter of cytomegalovirus. 
rtTA is a fusion of amino acids 1-207 of the tet repressor (TetR) and the negatively charged 
C-terminal activation domain (130 amino acids) of the VP16 protein of the herpes simplex 
virus. The plasmid pTet-On was originally described as pUHD17-1neo by [150] and is used 
to develop stable Tet-On cell line.  
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After a vector that contains a gene under the control of a tet-responsive element is transfected 
into a Tet-On cell line, the rtTA protein is only capable of binding the to TRE when bound by 
Doxycycline. Thus the introduction of Doxycycline to the system initiates the transcription of 
the genetic product.  
 
pTRE-Tight (Clontech) (Supplementary figure 2F) contains TRE-based promoter Ptight, when 
used in Tet-On system, the controlled expression of gene of interest is responsive to the rtTA 
regulatory protein. Ptight contains a modified tet-responsive element (TRE), which consists of 
7 direct repeats of a 36-bp sequence that contains the 19-bp tet operator sequence (tetO). The 
TREmod is just upstream of the minimal CMV promoter, which lacks the enhancer that is part 
of the complete CMV promoter. Consequently, Ptight is silent in the absence of binding of 
rtTA to the tetO sequences. The characteristics for functional optimization are the 7 tetO 
sequences that are closer together and no potential binding sites of endogenous transcription 
factors. As a result, Ptight demonstrates greater inducibility coupled with extremely low basal 
activity and supports the very highest levels of Tet transactivation. pTREtight was derivate 
from pTRE, originally described as pUHD10-3. 
 
pENTR11-psRANKL (Supplementary figure 3) is a pENTR11 vector containing cDNA 
sequence of psRANKL obtained by subcloning the extracellular domain of pRANKL cDNA 
and Igκ-leader sequence from pSecTagABC-psRANKL into pENTR11 (Invitrogen) using 
XhoI/SalI restriction sites. 
 
pLenti6/V5-psRANKL (Supplementary figure 4) is a pLenti6/V5-DEST vector into which 
extracellular domain of pRANKL cDNA and Igκ-leader sequence from pENTR11-psRANKL 
were transferred by using Gateway LR Clonase (Invitrogen). The correct sequence of the 
resulting pLenti6-psRANKL was confirmed by sequencing (Sequiserve) and used for 
lentiviral production. 
 
pLenti6/V5-rtTA-psRANKL (Neo)  (Figure 3.9A) is a lentiviral vector obtained by subcloning 
the floxed Neomycin resistance gene from lox2Neo plasmid into pLenti6/V5-rtTA-psRANKL 
(Bla) (cloned for other purposes). The correct sequence of the resulting pLenti6/V5-rtTA-
psRANKL (Neo) was confirmed by sequencing (Sequiserve) and used for electroporation. 
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pCAG-rtTA (Supplementary figure 5) is a mammalian expression vector having a chicken β-
actin promoter for high-copy constitute expression in mammalian cell lines, reverse tet-
responsive transcriptional activator (rtTA) and Neomycin resistance gene floxed with two 
cassettes for selection in mammalian cells. rtTA cDNA sequence is fused to bovine growth 
hormone poly A for high mRNA stability. This vector was designed by Nikolai Klymiuk 
(Institute of molecular animal breeding and biotechnology, Prof. Eckhard Wolf). 
 
pTRE-psRANKL (Supplementary figure 6) is a mammalian expression vector having 
pRANKL cDNA sequence upon regulation of TRE-based promoter Ptight and floxed 
Blasticidin resistance gene. psRANKL cDNA sequence is fused to bovine growth hormone 
poly A for high mRNA stability. In combination with pCAG-rtTA vector and Doxycycline, 
the expression of psRANKL from pTRE-psRANKL vector is achieved. This vector was 
designed by Nikolai Klymiuk (Institute of molecular animal breeding and biotechnology, 
Prof. Eckhard Wolf). 
 
2.3.2 Restriction, ligation and recombination reactions 
Restriction, ligation and recombination reactions were performed according to the 
manufacturers’ descriptions.  
Briefly, for the restriction reaction 10 µg of the plasmid were digested in the presence of 1× 
buffer (NEB, Schwalbach, Germany) and 2-3 U of restriction enzymes (NEB) at 37°C over 
night. The reaction was stopped by heat inactivation for 20 minutes at 60°C or by gel 
purification (see 2.3.3). 
In a 20 µl of the ligation reaction 50 ng of linearized destination vector was combined with a 
3-fold molar excess of linearized insert, mixed with 2× Quick Ligation buffer (NEB) and 1 µl 
of Quick T4 DNA Ligase (NEB) and incubated for 5 minutes at 25°C, followed by cooling of 
the reaction mixture on ice. A 10 nM of ligated plasmid was used for transformation into 
TOP10 competent bacterial cells (see 2.4.1).  
For the recombination reaction, a mixture of 300 ng of pENTR11 plasmid, 300 ng 
pLenti6/V5-DEST and 5× LR Clonase reaction buffer with 4 µl from LR Clonase (Invitrogen) 
were incubated for 4 hours at room temperature. The reaction was stopped by addition of 2 µl 
Proteinase K and incubation for 10 min at 37°C.  
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2.3.3 Gel purification  
The DNA extraction from agarose gel was performed according to the manufacturer’s 
description using a NucleoSpin Extract II kit (Macherey-Nagel, Düren, Germany). Briefly, the 
desired DNA fragment was excised from agarose gel, weighted, mixed with 2 times volume 
of NT buffer and dissolved at 50°C for 10 minutes. Next, the DNA was bind to the column, 
washed and finally eluted in 30 µl of prewarmed NE buffer. The purified DNA fragment was 
used for further cloning steps. 
 
2.3.4 Analyzing of clones 
6 or more bacterial colonies were picked and cultured over night at 37°C with 225 rpm 
constant shaking in 5 ml LB medium containing antibiotics.    
Plasmid DNA (pDNA) was isolated using GenElute Plasmid Miniprep Kit (Sigma-Aldrich) 
and following the manufacturer’s instructions. Briefly, the cells were pelleted, resuspended 
and lysed for 3 min at RT. The lysis was stopped with the neutralization solution and cell 
debris was pelleted by centrifugation. The supernatant was loaded on previously equilibrated 
column and washed twice with washing buffer. The pDNA was eluted in elution buffer (5mM 
Tris-HCl buffer pH8.0). The pDNA was digested with restriction enzymes to confirm the 
presence and orientation of the insert as well as the integrity of the vector (see 2.3.2).  
 
2.3.5 Maxi-prep of the plasmids 
From the correct clones, a bigger amount of pDNA was isolated by HiSpeed Plasmid Maxi 
Kit (Qiagen, Hilden, Germany) for the pENTR11 clone or EndoFree Plasmid Maxi Kit 
(Qiagen, Hilden, Germany) for pLenti6/V5 clones. The kits were used according to the 
manufacturer’s instructions. Briefly, the bacteria were pelleted and lysed and the cell debris 
was precipitate and filtrated. After the filtration the bacterial lysate was loaded on a column, 
washed, eluted and the pDNA was precipitated with isopropanol and pelleted by 
centrifugation. The pDNA pellet was washed with 70% ethanol, air-dried and resuspended in 
elution buffer (5mM Tris-HCl buffer pH8.0). The pDNA concentration was photometrically 
(Biophotometer, Eppendorf, Hamburg, Germany) measured and the integrity of vector was 
analyzed by digestion. Finally, the vector was sequenced to confirm that the gene of interest is 
in frame with the C-terminal tag using the CMV forward primer 5′-
CGCAAATGGGCGGTAGGCGTG-3′ and V5 epitope reverse primer 5′-
ACCGAGGAGAGGGTTAGGGAT-3′ by Sequiserve (Vaterstetten, Germany).  
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2.4 GENE TRANSFER 
2.4.1 Transformation of bacteria 
The final step of cloning procedure finished with bacterial transformation of desired plasmids. 
For the transformation were used two types of E. coli strains and protocol according to the 
manufacturer.  
For the transformation of lentiviral vectors into the Stbl3 competent cells, 5 µl of the 
recombination/ligation reaction was added to the cells and incubated for 30 minutes on ice. 
Next, the cells were heat-shocked for 45 seconds at 42°C and incubated at 37°C with 225 rpm 
constant shaking for 1 hour in 250 µl S.O.C. media (Invitrogen). Finally, the cells were plated 
on Ampicillin LB agar plates and left to grow for 12 hours at 37°C to obtain bacterial clones. 
For the transformation of TOP10 competent cells, the same protocol was used, except that the 
cells were heat-shocked for 30 seconds at 42°C. 
 
2.4.2 Lentivirus production 
For lentivirus production the ViraPower™ Lentiviral Expression System from Invitrogen was 
used. This system allows creation of a replication-incompetent HIV-1-based lentivirus that is 
used to deliver and express gene of interest in either dividing or non-dividing mammalian 
cells. The major components of the system include: an expression plasmid containing the 
gene of interest under the control of a constitutive promoters and elements that allow 
packaging of the construct into virions (e.g., 5′ and 3′ LTRs, Ψ packaging signal); an 
optimized mix of the three packaging plasmids (pLP1, pLP2 and pLP/VSVG) that supply the 
structural and replication proteins in trans that are required to produce the lentivirus; the 
293FT cell line, which allows production of lentivirus following cotransfection of the 
expression plasmid and the plasmids in the packaging mix. 
Briefly, cotransfection of the ViraPower™ Packaging Mix and the pLenti vector-containing 
gene of interest into 293FT cells produce a replication-incompetent lentivirus, which will be 
used to transduce a mammalian cell line. Once the lentivirus enters the target cell, the viral 
RNA is reverse-transcribed, actively imported into the nucleus [168,168] and stably integrated 
into the host genome [162,170]. After the lentiviral construct has integrated into the genome, 
the use of antibiotic selection generates a stable cell line for long-term expression studies.  
For production of the viruses an established protocol based on the manufacturer’s 
recommendations was used. Briefly, 24 x106 of 293FT cells were resuspended in Opti–MEM 
media (Invitrogen). Three plasmids pLP1, pLP2 and pLP/VSVG from ViraPower lentiviral 
packaging mix (Invitrogen) responsible for amplification and packaging of the viral particles 
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were mixed in ratio 3:1 with pLenti plasmids in Opti-MEM media and Lipofectamine 2000 
(Invitrogen). The cells were resuspended in the media containing plasmids–Lipofectamine 
2000 complex and incubated in cell culture incubator at 37°C/5%CO2 for 6 hours. After 
incubation time, the media was replaced with complete culture media and the cells were 
further cultured for 48 hours. Virus-containing media were harvested, filtered though 0.22 µm 
filter and stored in aliquots at -80°C. All viral material was produced in S2-laboratory and 
stored at Max-von-Pettenkofer-Institute, Virology Section, University of Munich leaded by 
Prof. Dr. med. Ulrich Koszinowski.   
 
2.4.3 Transduction of target cells 
For transduction, the cells were incubated for minimum of 30 min with 16 g/ml Polybrene 
(Sigma-Aldrich) in a growth media. Next, viral supernatant was added in a 1:2 dilution in 
normal growth media. One day after transduction, the medium was replaced by fresh, nonviral 
medium and successfully transduced cells were selected with 10 µg/ml Blasticidin 
(Invitrogen) for 10 days. Finally, the cells were tested for a presence of viral particles by 
using HIV-1 p24 ELISA kit (PerkinElmer, Wiesenbaden, Germany). Only virus-free cells 
were transfer to S1-laboratory and used in the following experiments.  
 
2.4.4 Transfection 
For transfection of the cell an established protocol based on Lipofectamine 2000 Reagent 
(Invitrogen) was used. Briefly, 90-95% confluent cell layer and 1 µg of the plasmid were used 
for 6-well dish. Next, the DNA plasmid and Lipofectamine were diluted in Opti-MEM media 
(Invitrogen) without serum in separated tubes and incubated for 5 minutes at room 
temperature. After incubation, DNA and Lipofectamine were mixed in ratio 3:1 and incubated 
for further 20 minutes at room temperature. Finally, the complexes were added to the cells 
and incubated in cell culture incubator at 37°C/5%CO2 for 6 hours. After incubation time, the 
media was replaced with complete culture media and the cells were further cultured for 
further experiment. 
 
2.4.5 Electroporation 
For introduction of desired genes into the primary porcine cells, the Amaxa Nucleofector 
technology (Lonza, Cologne, Germany) was used. This procedure was preformed by 
Annegret Wünsch at the Institute of Molecular Animal Breeding and Biotechnology (LMU, 
Prof. Eckhard Wolf).  
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2.5 GENOMIC ANALYSIS 
Genomic analysis, of isolation, Southern blot and genomic PCR, were performed by Nikolai 
Klymiuk at the Institute of molecular animal breeding and biotechnology (LMU, Prof. 
Eckhard Wolf). 
 
2.6 TRANSCRIPTOMIC ANALYSIS 
2.6.1 Isolation of total RNA 
From the cells 
Isolation of total RNA from cells was performed with RNeasy Mini kit (Qiagen). Briefly, the 
cells were washed with PBS, trpysinized and lyses with RLT buffer and 1% ß-
mercaptoethanol. The cell lysates were then filtrated through QIAshredder spin columns, 
mixed with isovolume of 70% ethanol and loaded on RNeasy spin columns. Contaminants 
from genomic DNA were digested with 10U of DNAse (RNAse free DNAse Set, Qiagen) for 
15 min at RT. Finally, columns were washed twice with washing solution and dried by 
centrifugation at maximum speed. High-quality total RNA was eluted in RNase-free water 
and measured spectrophotometrically (Biophotometer, Eppendorf) for evaluation of the RNA 
concentration and purity. Furthermore, the quality of the RNA was checked by gel 
electrophoresis. Briefly, 500 ng of the RNA was mixed with loading dye, denaturated for 10 
min at 70°C, placed on ice for 3 min and loaded on the 1% agarose gel. The good RNA 
quality was evaluated if showed 2 bands on the gel (18S and 28S).  
 
From the tissues 
Isolation of total RNA from tissues was performed with RNeasy Mini kit (Qiagen). Briefly, to 
isolate the RNA, 30 mg of the frozen tissue was weighted, disrupted using a mortar and pestle 
in liquid nitrogen and homogenized by RLT buffer and 1% ß-marcaptoethanol using a 
QIAshredder spin column following the procedure described above. 
 
2.6.2 cDNA synthesis 
The cDNA synthesis was performed with Cloned AMV First-Strand cDNA Synthesis Kit 
(Invitrogen) following the manufacturer’s protocol. Briefly, 1 µg of total RNA, random 
primers and 10 mM dNTPs were heated for 15 min at 65°C. The denatured RNA was added 
to a mixture of PCR buffer, 15 U of reverse transcriptase, 40 U of RNAse inhibitor and 0.1 M 
DTT and the mixture was incubated for 1 hour at 50°C.  
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2.6.3 RT-PCR 
A specific amount of cDNA (determined by the expression of GAPDH) was added to a master 
mix containing 1×PCR buffer, 1.5 mM MgCl2, 0.2 mM dNTPs, 0.5 µM primers 
(Supplementary table 1) and 1 U Taq DNA polymerase (Invitrogen). The PCR reactions were 
run on MG Research PCR machine (BioRad, Munich, Germany). Normally, the PCR 
programs had 3 min 95°C, 30 cycles of amplification as each cycle consisted of denaturation 
(94°C for 30 sec), annealing (55°C for 30 sec) and elongation (72°C for 60 sec) steps, 10 min 
72°C, 4°C forever. The amplified products were analyzed on 2% agarose gels and visualized 
by ethidium bromide. As a reference for the correct size of the amplified product a 100 bp 
molecular weight standard (Invitrogen) was used. Pictures with different exposure times were 
taken by using a gel imaging system (Vilber Lourmat Deutschland GmbH, Hochdorf Riß, 
Germany). 
To be sure that RNA is pure from DNA contaminations; the PCR was also preformed on 
RNA samples. 
 
2.6.4 Gel electrophoresis 
To prepare the gel for the electrophoresis, the agarose powder was weighted to obtain a 
desired percentage and completely dissolved in 1×TAE buffer by heating. Next, the gel 
solution was left to cool down, 0,003% of ethidium bromide was added and gel was poured 
into the gel tray with well comb fixed properly. After the gel has been cooled completely and 
solidified, the comb was removed and the tray was inserted properly into the gel chamber. 
The 1×TAE buffer was poured into the chamber to cover the gel and fill the wells. Finally, 10 
µl (for RNA and DNA) or 20 µl (for cDNA) of samples/loading dye solution were pipetted 
into the appropriate wells of the gel and the gel was run at 80-120 V (according to the size of 
the gel) for 45 minutes. 
 
2.7 PROTEOMIC ANALYSIS 
2.7.1 Histology 
Cell plating and fixation 
1x105 of the each cell type were plated on glass slides and were cultured in complete media 
for maximum of 3 days. After this the media was removed, cells were rinsed with PBS (w 
Ca/Mg, PAA) and fixed with 4% PFA (Merck) for 10 min at RT. After the fixation the slides 
were washed with PBS, air-dried and immediately used or stored at -20°C for up to 2 weeks.   
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Immunofluorescence staining 
The fixed cells were rehydrated in PBS (3x5 min at RT, PAA) and permeabilized with 0.2% 
Triton X-100/PBS (Sigma) for 15 min. Image enhancer solution (Invitrogen), which reduce 
the unspecific binding of secondary antibodies, was applied for 45 min. Blocking was 
performed with 2% BSA/PBS + 1.5% goat serum (Dianova, Hamburg, Germany) for 2 hours 
and it followed by addition of primary antibodies (Supplementary table 2) for 1 hours at 37°C. 
After PBS washing (3x5 min at RT), secondary antibodies were added for 30 min at room 
temperature. Finally, the slides were washed with PBS (3x5 min) and nuclear contrastaining 
was performed with a 4',6-diamidino-2-phenylindole (DAPI, Invitrogen) in dilution of 1:10 
000 in blocking solution. Following a PBS washing (3x5 min) the slides were mounted with 
Mowiol anti-fading media (6 g glycerol, 2.4 g Mowiol, 12 ml 0,2 M Tris-HCl pH 8.5, 0.024 g 
DABCO and 6 ml H2O). Negative controls for antibody were carried out on the same slide by 
omitting the primary antibody. The stained slides were stored over night at 4°C. Pictures with 
different magnification were taken on Axioskope2 microscope (Carl Zeiss MicroImaging 
GmbH). 
 
DAB staining 
For DAB staining, the slides were washed with phosphate-buffered saline (PBS), 
permeabilized with 0.2% Triton X-100/PBS for 15 min and endogenous peroxidase activity 
was quenched by application of 3% hydrogen peroxide for 30 minutes at room temperature. 
Blocking solution consisting of 2% BSA/PBS + 1.5% goat serum + 1.5% horse serum 
(Dianova) was applied to the slides for 2 hours at RT and it followed by incubation of primary 
antibodies (Supplementary table 2) overnight at 4°C. Incubation with secondary biotinylated 
goat-anti-rabbit antibody (Vector Laboratories, Burlingame, CA) was performed for 1 h at 
37°C followed by application of avidin-biotin complex for half hour at room temperature. 
Diaminiobenzidene (DAB, Vector Laboratories) was used as the colorizing agent. Following 
PBS washing (3x5 min) the slides were mounted with DPX anti-fading media (Sigma-
Aldrich). Negative controls for antibody were carried out on the same slide by omitting the 
primary antibody. The stained slides were stored over night at room temperature. Pictures 
with different magnification were taken on Axioskope2 microscope (Carl Zeiss MicroImaging 
GmbH). 
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2.7.2 Western blotting 
Protein extraction 
For protein extraction from the cells, RIPA extraction buffer composed of 0.1% (w/v) sodium 
dodecyl sulfate (SDS), 1% (w/v) Na-DOC, 1% (v/v) Triton X-100, 50 mM Tris–HCl (pH 8,2), 
150 mM NaCl, 10 mM ethylenediamine tetraacetic acid (EDTA; pH 8.0) and 20 mM NaF 
containing a mixture of protease inhibitors (Complete Mini, EDTA-free, Roche, Penzberg, 
Germany) was used. After typsinization and washing, the cells were lysed in the above buffer 
by incubation on ice for 30 min. After incubation cells were disrupted by sonication and 
incubated on ice for additional 30 min. The insoluble cell debris was removed by 
centrifugation at 10 000 g for 10 min at 4°C. The supernatant containing protein was 
aliquoted and stored at -80°C.  
For protein analysis from supernatant, the media was not change for at least 2 days. Next, the 
supernatant was collected and filtered through 0,22 µm pore size filter (Milipore, Schwalbach, 
Germany) to remove cell debris. Finally the supernatant was aliquoted and stored at -20°C. 
For the protein extraction from the tissues, the same protocol as the one used for the cells was 
used, except that 0,6 g of the tissue was disrupted using mortar and pestle in liquid nitrogen 
and lysed in RIPA buffer. 
 
BCA assay 
The total protein amount from cells, supernatants and tissues was measured by using the 
bicinchoninic acid (BCA) protein assay kit (Thermo Scientific) by ELISA. Briefly, the protein 
concentration was determined based on a chemical reaction where BCA interact with the 
cuprous cations that are reduced by the proteins in an alkaline media. As a result an intense 
purple-coloured reaction is observed and the intensity of the color correlates with the protein 
concentration. The protein amount was calculated using a standard curve that is built by serial 
BSA dilutions. The measurements are performed at 450 nm on microtitre-plate reader 
(Thermo Scientific).  
 
SDS-PAGE 
Protein extracts were mixed with 4×Laemmli buffer (200 mM Tris-HCl pH 6.8, 40% glycerol, 
10% SDS, 30% 2-mercaptoethanol, 0.02% bromphenolblue and 0.2 M DTT) and were boiled 
for 5 min at 99°C. The protein mixtures were spined down and loaded on 12% acrylamide 
gels (BioRad). The electrophoresis was performed in 1×running buffer formulated from 0.25 
M Tris-base pH 8.3, 1% SDS and 1.92 M glycine. For a molecular weight standard, Seeblue 
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plus 2 protein marker (Invitrogen) was used. The electrophoresis was run at 60 for 1 gel or 
100 mA for 2 gels. The procedure continued protein transfer to PVDF membrane (Roche) (see 
Protein transfer).    
 
Protein transfer 
The protein transfer was performed by using the vertical “wet” transfer method. In brief, gel 
loaded with proteins was equilibrated for 15 to 20 min in 1×blotting solution containing 250 
mM Tris-base and 1.92 mM glycine. During this equilibration time, the PVDF membrane was 
incubated in methanol, rinsed in water and soaked in 1×blotting buffer. The Western blot 
setup was then assembled. The protein transfer was performed over night with 30 V at 4°C. 
After the transfer, the gel was preceded with Coomassie staining and immunodetection. 
 
Coomassie staining 
The gel was first incubated in isopropanol fixation solution consisting of 10% acetic acid and 
25% isopropanol (Merck) and then in Coomassie staining solution formulated from 7% acetic 
acid, 40% methanol (Merck) and 0.025% Coomassie brilliant blue (ROTH). In this solution 
the gel was boiled for 30 sec and gently shaken for 20 min at RT. Destaining solution 
consisting of 7% acetic acid and 40% methanol was applied to the gel for 12 hours with gentle 
shaking. This staining was used to analyze the quality loading and transfer of the protein 
extracts. 
 
Protein immunodetection 
The PVDF membrane was incubated with blocking solution consisting of 5% skim milk/TBS-
T20 for 1,5 hour with gentle shaking. Then, primary antibody (Supplementary table 2), 
diluted in the blocking solution, was applied with vigorous shaking at 4°C over night. The 
membrane was washed 4x7 min with TBS-T20 washing solution consisting of 1 mM Tris-
base pH 7.4, 150 mM NaCl and 0.05% Tween20 and secondary antibody, diluted in the 
blocking solution, was applied to the membrane for 1 hour with vigorous shaking. Finally, the 
membrane was again washed 4x7 min with TBS-T20 and proteins were visualized by using 
chemiluminescent ECLplus solution (GE Healthcare, Munich, Germany) and detection film 
(Lumi-film chemiluminescent, Roche) using detector and fixator solution (Merck).  
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2.7.3 ELISAs 
sRANKL ELISA 
To determine the amount of RANKL protein secreted in the medium, concentration of the 
protein in the cell culture supernatant was measured. A sRANKL enzyme-linked 
immunosorbent assay (ELISA) was performed using the Biomedica sRANKL ELISA kit 
(Vienna, Austria). A standard curve was generated using two-fold serial dilutions ranging 
from 200 to 25 pg/ml.  
 
Cathepsin K ELISA 
To determine the amount of Cathepsin K produced by the active osteoclast, we measured the 
concentration of the protein in the serum of wild type and transgenic pig. A Cathepsin K 
enzyme-linked immunosorbent assay (ELISA) was performed using the Biomedica Cathepsin 
K ELISA kit. A standard curve was generated using two-fold serial dilutions ranging from 
300 to 11 pmol/l. 
 
CrossLaps ELISA 
For the quantification of degradation products of C-terminal telopeptides of Type-l collagen 
(CTX) during bone resorption, we measured the concentration of the CTX protein in the 
serum of wild type and transgenic pig. A CrossLaps enzyme-linked immunosorbent assay 
(ELISA) was performed using the Nordic Bioscience Serum CrossLaps ELISA kit (Herlev, 
Denmark). A standard curve was generated using two-fold serial dilutions ranging from 2 to 
0,114 ng/ml. 
 
2.8 OSTEOCLAST FORMATION AND ANALYSIS 
2.8.1 Isolation of porcine osteoclast precursor cells by density gradient 
centrifugation 
Bone marrow was withdrawn from the posterior iliac crest of the pelvic bone from wild type 
swine. To prevent clotting, bone marrow was treated with 1% sodium-heparin and stored on 
ice before processing. Bone marrow was subjected to isolation of mononuclear cells, which 
contain the osteoclastic precursor cells. Density gradient centrifugation was used to separate 
the mononuclear precursor cells from other elements in blood. Therefore, the bone marrow 
was diluted 1:4 with PBS and carefully layered on top of the Ficoll–Paque. The tubes were 
centrifuged with 350 g at 20°C for 30 min. The mononuclear hematopoietic precursors 
accumulating at the interface between PBS and Ficoll-Paque were transferred in 50 ml-tubes 
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resulting ~10 ml of mononuclear cells. These tubes were filled with PBS and centrifuged with 
350 g at 20°C for 10 min. Pellets were washed with PBS and resuspended in growth medium. 
Cell solution of 10 µl were stained with 990 µl Trypan-blue to assess viability and counted in 
a Neubauer counting chamber. To dispose the culture of contaminating lymphocytes, the cells 
were purified for adherence by stimulation with 5 ng/ml M-CSF (human recombinant 
Macrophage-Colony Stimulating Factor, Sigma-Aldrich). Therefore, the non-adherent cells 
were washed off at day four of culture, so that only the adherent monocytes were used for 
further experiments.  
 
2.8.2 Osteoclastic cell culture 
Porcine osteoclast precursor cells isolated from bone marrow were cultured for initially 4 days 
in growth medium supplemented with 5 ng/ml M-CSF (Sigma-Aldrich). Next, the cells were 
stimulated for further 14 days with 20 ng/ml RANKL (recombinant human soluble RANK 
Ligand, PeproTech) to generate osteoclasts. 
 
2.8.3 Osteoclasts visualization 
TRACP assay 
For TRACP assay experiment, the cells were cultured in 6-well dish and after 14 days of 
stimulation with 5 ng/ml M-CSF (Sigma-Aldrich) and 20 ng/ml RANKL (Peprotech), fixed 
with 10% glutaraldehyde solution (Sigma-Aldrich) for 15 minutes at 37° and washed 2 times 
with PBS. The fixed cells were stained in TRACP-staining solution for 30 min at 37°C. 
TRACP staining solution consisted of 5 mg Naphtol AS-MX Phosphate and 15 mg Fast Red 
Violett LB Salt in 50 ml TRACP-buffer (0,2 M sodium-acetate, 0,2 M acetic acid,  0,3 M 
sodium-tartrate). Mature osteoclasts were defined as highly TRACP-positive cells containing 
3 or more nuclei. Photomicrographs were taken with axiocam magnetic resonance on an 
Axiovert-microscope (Carl Zeiss MicroImaging GmbH). 
 
Phalloidin staining 
For phalloidin staining osteoclastic precursor cells were cultured on sterile glass cover slides 
and stimulated to obtain osteoclast. The slides were fixed with 4% PFA at room temperature 
for 10 min, permeablizated with 0,1% Triton-X (Sigma-Aldrich) for 15 minutes at room 
temperature and stained with Alexa Fluor 488-phalloidin in 1:20 dilution for 1 hour at 37°C. 
Nuclei were stained with propidium iodide (Sigma-Aldrich). Analysis was done with a 
confocal LSM 510 (Carl Zeiss MicroImaging GmbH) equipped with Plan-Apochromat 
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63×/1.4 Oil DIC.  Propidium iodide and Alexa Fluor 488-phalloidin (excitation 488 and 543) 
were detected in dual-channel mode using LP560nm and BP505-530nm emission filters. 
 
Concanavalin A staining 
For Concanavalin A staining osteoclastic precursor cells were cultured on sterile glass cover 
slides and stimulated to obtain osteoclast. The slides were fixed with 4% PFA at room 
temperature for 10 min and stained with Concanavalin A antibody (24 µg/ml, Invitrogen) for 
45 minutes at room temperature in the dark. Nuclei were stained with 4',6-diamidino-2-
phenylindole (DAPI) in dilution of 1:10 000 in PBS solution and the analysis was done with a 
Axioskope2 microscope (Carl Zeiss MicroImaging GmbH). 
 
Giemsa staining 
For Giemsa staining, osteoclastic precursor cells were cultured in 6-well dishes and stimulated 
to obtain osteoclast. The cells were fixed with 4% PFA at room temperature for 10 min and 
stained with 5% Giemsa´s stain solution (Gibco, Karlsruhe, Germany) for 3 hours at 37°C. 
Following a H2O washing (3x5 min) the dishes were differentiated with 0,5% aqueous acetic 
acid solution for 30 seconds and finally covered with water. Pictures with different 
magnification were taken on Axioskope2 microscope (Carl Zeiss MicroImaging GmbH). 
 
2.8.4 In vitro osteoclastogenesis assays 
To determinate whether the psRANKL is capable of inducing osteoclastogenesis, the 
osteoclastic precursor cells were seeded in 6-well dish and cultured in medium supplemented 
with 5 ng/ml M-CSF (Sigma-Aldrich) for 4 days. At day 5, osteoclastic precursor cells were 
stimulated with 20 ng/ml hsRANKL (hsRANKL + M-CSF) or transfected with 1 µg pLenti6-
psRANKL construct using Lipofectamine Reagent 2000 (Invitrogen) (see 2.4.4). Two 
negative cell controls were carried on, one cell control was stimulated with 5 ng/ml M-CSF 
(Sigma-Aldrich) and other was cultured in normal growth media without stimulants. Cultures 
were maintained for additional 3 or 7 days and proceeded further to confirm the identity of the 
osteoclasts.  
To be sure that transfected osteoclastic precursor cells are expressing psRANKL protein, three 
days after transfection the supernatant from cells cultured with M-CSF alone and transfected 
with psRANKL + M-CSF was collected and psRANKL protein was measured by sRANKL 
ELISA (Biomedica) as mentioned above. The TRACP cytochemistry was preformed on day 7 
after transfection in 6-well dish as described above. Mature osteoclasts with highly TRACP-
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positive cells containing 3 or more nuclei were counted in the whole 6-well dish and per each 
condition under the Axiovert-microscope (Carl Zeiss MicroImaging GmbH).  
For the detection of CA-II, RNA was isolated as described in 2.6.1 and reverse transcription 
was done (see 2.6.2) from cells cultured in 6-well dish for 7 days in medium, with 20 ng/ml 
hsRANKL + 5 ng/ml M-CSF, with 5 ng/ml M-CSF and transfected with psRANKL, 
respectively. The primer set for CA-II (Supplementary table 1) was used and PCR 
amplification was carried out. The PCR results were visualized on 2% agarose gel (see 2.6.4). 
 
Resorption assay 
For quantitative measure of bone resorption, 10 000 osteoclastic precursor cells were plated 
per well on 96-OsteoAssay human bone plate (Lonza) and cultured in medium, with 20 ng/ml 
hsRANKL + 5 ng/ml M-CSF, with 5 ng/ml M-CSF and 5 ng/ml M-CSF + 0,2 µg transfected 
with psRANKL, respectively. Two wells were left without cell for the background values for 
data calculation. At day 0 and day 3 after transfection, the supernatant was collected and used 
in CalciFluor assay (Lonza) to measure calcium that is released as a result of osteoclast-
mediated resorptive activity. Briefly, after collecting the supernatant the calcium detection 
reagent was dissolved and pipetted in 96-well black-welled assay plate. Next, the probes and 
standards were added and the fluorescence was determinated by fluorimeter (Safire II, 
TECAN, Crailsheim, Germany) by excitation of 555λ and emission of 577λ. Finally, the 
calcium concentration of the samples was read out from the standard curve. 
 
2.9 GENERATION OF TRANSGENIC ANIMALS 
All procedures of generation transgenic pigs from oocyte and donor cell preparation over 
somatic cell nuclear transfer to the embryo transfer were performed by Barbara Keßler, 
Mayuko Kurome and Eleonore Schilling at the Institute of Molecular animal breeding and 
biotechnology (Prof. Eckhard Wolf) according to German laws, regulations and institutional 
guidelines. All animals subjected to this study displayed a good health status. 
 
Tissue preparation 
After sacrificing the animals, different organs were taken, cut into small pieces and snap 
frozen in liquid nitrogen. The frozen tissues were preserved at -80°C before processing. 
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Application of Doxycycline 
Doxycycline was fed in the form of tablets (Doxy 200®, CT Arzneimittel GmbH, Berlin, 
Germany; one tablet contains 200 mg Doxycycline). For the first in vivo stimulation 
experiment, a daily dose of 3.2 mg/kg body weight was applied for periods of 10 days, on day 
11 the dose was doubled and applied for further 10 days. For second stimulation experiment, 
a daily dose of 6,3 mg/kg body weight was applied for 10 days, on day 11 the dose was 
doubled and applied for further 10 days, on day 21 the dose was again doubled and applied 
for 10 days and on day 31 the dose was again doubled and applied for 10 days. In figures 3.22 
and 3.23, 0,25X is indicating a dose of 3,2 mg/kg body weight, 0,5X a dose of 6,3 mg/kg 
body weight, 1X a dose of 12,5 mg/kg body weight, 2X a dose of 25 mg/kg body weight and 
4X a dose of 50 mg/kg body weight, respectively. Blood samples were taken from the Vena 
jugularis prior to Doxycycline treatment and at different time points thereafter (on day 3, 6, 
10) and were analyzed by sRANKL, Cathepsin K (only for first stimulation) and CrossLaps 
ELISA (only for first stimulation) (2.7.3). 
 
2.10 MICROSCOPY 
The microscopes and cameras used in this thesis are purchased from Carl Zeiss MicroImaging 
GmbH. Axiovert100 microscope was used for taking immunofluorescent microphotographs. 
Pictures were taken with 10× and 40× objectives and using AxioCam MRm black-white 
camera. Axiovert 40CFL was used for imaging of DAB-stained cells, TRACP-stained and 
Giemsa-stained osteoclast. Objectives having 5×, 10×, 20× and 40× magnifications were 
used. For taking pictures was used AxioCam ICc3 colour camera. Laser scan microscope 
(LSM 510, Carl Zeiss MicroImaging GmbH) was used for imaging of phalloidin-stained cells. 
 
2.11 COMPUTIONAL SOFTWARES 
In this thesis a number of specialized programs were used for processing and analyzing the 
obtained data. The charts were created by using GraphPad Prism 5 (Systat Software). 
Photomicrographs were processed with using AxioVision LE software (Carl Zeiss 
MicroImaging GmbH) and Adobe Photoshop CS2 program (Adobe Systems Incorporated). 
For cloning experiments, Clone Manager Suite 7 was used. 
The following links were used: 
• www.ncbi.nlm.nih.gov/sites/entrez - major source of publications, 
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• blast.ncbi.nlm.nih.gov/Blast.cgi - NCBI-BLAST for regions of similarity between 
biological sequences,  
• www.ebi.ac.uk/Tools/clustalw/index.html - ClustalW for multiple sequence 
alignment,  
• www.ch.EMBnet.org – Boxshade for pretty printing and shading of multiple-
alignment files,  
•  www.cbs.dtu.dk/services/NetNGlyc - NetNGlyc 1.0 Server for prediction N-
glycosylation sites in proteins using artificial neural networks that examine the 
sequence context of Asn-Xaa-Ser/Thr sequons and  
•  smart.embl-heidelberg.de - SMART Program (Simple Modular Architecture Research 
Tool) for the identification and annotation of genetically mobile domains and the 
analysis of domain architectures. 
 
2.12 STATISTICS 
The statistical relevance between groups was determinated using one-way analysis of variance 
(ANOVA), or by two-sample T-test on GraphPad Prism 5 (Systat Software). Graphs and bar 
charts show mean values and SEM. The ELISA enzymatic and colorimetric experiments, such 
as osteoclast quantification consisted of minimum 3 independent repeats, each performed in 
duplicates. PCR, western blot and staining results have been reproduced at least twice.  
The figure bar charts represent mean and standard deviation of minimum three independent 
experiments. A value of p<0.05 was considered significant. 
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3. RESULTS 
 
3.1 CLONING AND FUNCIONAL CHARACTERIZATION OF THE 
PROCINE EXTRACELLULAR DOMAIN OF RANKL (psRANKL) 
3.1.1 Cloning and sequence analysis of extracellular domain of porcine 
sRANKL 
To isolate a porcine extracellular domain of RANKL, the soluble functional form was cloned 
and over-expressed. For this purpose, the primers were constructed based on published 
extracellular domain of human RANKL cDNA sequence (NG_008990.1) obtained from 
BLAST search. Since RANKL is expressed by osteoblast, total RNA was extracted from this 
cell type and used as a template for RT-PCR for cloning porcine sRANKL (psRANKL). 
Using human RANKL-specific primers (Supplementary table 1), several potential psRANKL 
cDNAs were amplified by RT-PCR. Five clones were sequenced and exhibited the identical 
sequences. Finally, a cDNA of 731 bps and a protein of 243 amino acid residues with 28,2 
kDa molecular weight was generated. Furthermore, the recently published gene sequence 
(GenBank Accession No. CU024906) and our cloned cDNA has 100% identity to the genome 
sequence. This fragment coding for the extracellular portion was amplified by PCR, gel-
purified and subcloned into the expression vector having the Igk-leader signal sequence to 
obtain secreted form of porcine sRANKL. Sequencing confirmed that the insert formed 
correct open reading frame with the leader signal sequence of the parent plasmid. Finally, the 
extracellular region having Igk-leader signal and porcine sRANKL was subcloned into 
lentiviral pLenti6/V5-DEST vector generating a cDNA template of 842 bps and a protein of 
280 amino acids with molecular weight of 31,7 kDa with predicted pI of 6,90. Amplicon was 
sequenced, published under GeneBank accession number DQ523616 and aligned to published 
human, rat and murine cDNA sequences. Nucleotide homology to the human sequence at the 
corresponding region is 87%. Homology between the respective region from Mus muscullus 
and Rat norvegicus sequences are 79%. The protein sequences of extracellular domain of 
porcine, human (GeneBank Acc. No.: AAB86811.1), rat (Q9ESE2) and murine 
(AAB86812.1) sRANKLs are compared in Figure 3.1A, which shows that porcine and human 
share 90% homology, porcine and rat 81% and porcine and mouse 80% homology, 
respectively. The homology between the species is strong along the entire sRANKL molecule 
and the strongest sequence similarity appears to be at their carboxyl regions. Furthermore, the 
glycosylation sites are conserved among all four sRANKL proteins. A highly identity 
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between porcine and human sequence suggest that the function of this gene could be highly 
conserved. In addition, phylogenic analysis showed that psRANKL is more related to human 
than to rat and murine (Figure 3.1B). To predict structural domains in psRANKL, the putative 
amino acid sequence was analyzed using SMART program. As shown in Figure 3.1C, a TNF 
domain is located at C-terminus of newly cloned psRANKL. Similar domain can be predicted 
in sRANKL from human, rat and mouse, indicating that the TNF domain is a common 
characteristic of RANKL from different species. 
 
Figure 3.1.: Multiple alignment, phylogenetic tree and architecture of deduced amino acid sequences for 
sRANKLs. (A) Alignment of the predicted amino acid sequences of porcine (ABF81680), human (AAB86811), 
rat (Q9ESE2) and murine (AAB86812) sRANKL proteins. The number indicates the amino acid position. 
Identical amino acid residues are marked with black block and asteroids, while similar amino acid residues are 
marked with gray color and dots on consensus line. Conserved predicted N-glycosylation sites are indicated by 
asterisks and were determinated using the NetNGlyc 1.0 Server. Right/left arrow marks the beginning/end of the 
TNF-like core domain within extracellular region. (B) A phylogenetic tree of the amino acid sequences of 
porcine, human, murine and rat sRANKLs. The uprooted tree was built using the neighbour-joining method with 
program ClustalW based on the alignment of sRANKL protein sequences. The scale bar is 0,05 representing 
genetic distance. (C) Architecture of psRANKL predicted by SMART. The TNF domain is showed boxed. The 
number indicates the amino acid position. 
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3.1.2 Over-expression of porcine sRANKL in porcine fetal fibroblast 
To generate stable over-expressing porcine fetal fibroblast (pFF), expression construct 
pLenti6/V5-psRANKL (Supplementary figure 4) was used to generate lentivirus, which was 
used to transduce the porcine cells. As a control for over-expression, the wild type cells were 
carried out thought the whole experiment. Next, to examinate over-expression of psRANKL, 
RT-PCR, Western blot, ELISA and immunocytochemistry were performed.  
 
Figure 3.2.: Over-expression analysis of porcine sRANKL in wild type and porcine sRANKL-transduced pFFs 
on mRNA and protein level. (A) Total RNA from wild type and psRANKL-transduced pFFs was used for RT-
PCR of psRANKL mRNA. Expression of psRANKL mRNA was detected in psRANKL-transduced pFF, while 
no expression was detected in untransduced cells. No contamination of genomic DNA was found in both 
samples performing PCR without RT. The expression of psRANKL was normalized to the expression of 
GAPDH gene. (B) Total protein and supernatant from wild type and psRANKL-transduced pFFs was used for 
Western blot analysis. A strong expression can be found on protein level in transduced cells, while there was no 
visible expression of psRANKL in untransduced cells. The blots were stripped and reprobed with β-actin to 
normalize for the amount of loaded protein. (C) sRANKL ELISA of the supernatant collected from wild type 
and psRANKL-transduced pFFs. A strong secretion can be found in transduced cells, while there was no 
secretion of psRANKL from wild type cells. 
 
RANKL over-expression on mRNA level has been exanimate in the genetically modified 
porcine fetal fibroblast (psRANKL-pFF) and compared to the wild type cells. To be sure that 
only the transgene is amplified, the primers were designed in a way to bind on 3´ end of Igk-
leader signal sequence and 5´ end of psRANKL sequence generating a single transcript of a 
411 bps. RNA-control PCR was also performed, by omitting reverse transcriptase step, to 
exclude cDNA contamination. A strong expressional level of psRANKL mRNA was detected 
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in psRANKL-transduced cells, whereas no visible expression signal could be detected in 
untransduced wild type cells (Figure 3.2A). On a protein level, an over-expression of a 
psRANKL in transduced cells could be also seen comparing both cell types, using Western 
blot analysis. Western blot analysis of harvested media revealed a secreted psRANKL protein 
of about 30 kDa in psRANKL-pFF (Figure 3.2B). No band was found in untransduced cells. 
To quantify the amount of secreted psRANKL in the supernatant, a sRANKL-specific ELISA 
system of the supernatant from both cell types was performed and found a significant 
secretion of a psRANKL in transduced cells (Figure 3.2C). Therefore, the fusion protein 
psRANKL was expressed as expected in the soluble form. To further confirm these results 
and to show localization of psRANKL protein, two types of immunocytochemistry, DAB 
staining and immunofluorescence using an anti-RANKL-antibody as primary antibody, were 
preformed on psRANKL-pFF and wild type cells. In both immunocytochemistral analyses, 
psRANKL protein was primarily located around the nucleus but also in cytoplasm of the 
psRANKL-pFF, while no or very low background psRANKL expression was detected in 
untransduced pFFs (Figure 3.3A and B).  
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Figure 3.3.: Immunocytochemistral analysis of over-expression of psRANKL protein in wild type and 
psRANKL-transduced pFFs. (A) DAB-immunostaining of the cells. A strong positive signal indicated by the 
brown color reaction by the DAB chromagen was detected in transduced cells, while there was very low 
background signal in wild type cells. (B) Immunofluorescence staining of the cells. The negative control without 
primary anti-RANKL-antibody and the wild type pFF show hardly fluorescence signal. A strong Alexa Fluor 
488 signal (green) in transduced pFF indicates a high expression of psRANKL. Green: RANKL staining; blue: 
DAPI nuclear counterstaining. 
 
3.1.3 Characterization of porcine osteoclasts 
Induction of multinucleated giant cells by treatment of monocytes with hsRANKL and M-CSF 
To obtain osteoclast cultures and to characterize them, porcine osteoclastic precursor cells 
were treated with 20 ng/ml hsRANKL and 5 ng/ml M-CSF for 14 days. The cultured 
osteoclastic precursor cells from bone marrow were of typical spindle-shaped morphology 
(Supplementary figure 1E). First osteoclast appeared in culture on day 3-6 after stimulation. 
The osteoclasts´ culture had a morphology varied from small multinucleated cells localized 
within a dense fibroblast/stromal cell layer to giant cell that had lost contact to the 
surrounding cell layer (Figure 3.4A). To ensure, that the generated cells were indeed 
osteoclasts, they were tested for important specific characteristics. First the morphology of the 
resulting cells (multinuclearity, formation of actin rings with podosomes) was analyzed. A 
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confluent layer of multinucleated cells was observed by light microscope (Figure 3.4B). The 
increase in osteoclast numbers was accompanied by the appearance of multinucleated cells 
with typical osteoclast morphology: large size, flat morphology, multinucleation and intense 
staining for TRACP, an osteoclast marker (Figure 3.4C and D). The identity of the osteoclast  
 
Figure 3.4.: Osteoclast differentiation in cultures stimulated with hsRANKL and M-CSF for 14 days, their 
morphology, Giemsa and TRACP staining. (A) Phase-contrast figure showing typical osteoclast morphology: 
large size, flat appearance, and multinucleation. Marked black lines are indicating the border of the osteoclasts. 
(B) Giemsa staining of porcine osteoclast under light microscopy. (C & D) TRACP staining of porcine osteoclast 
under light microscopy. The osteoclasts are showing strong staining for TRACP.  
 
was further confirmed by staining of the actin by confocal microscopy. Osteoclastic precursor 
cells were cultured on glass slides and induced with hsRANKL and M-CSF to differentiate 
for 14 days. Next, they were stained for phalloidin actin ring (Figure 3.5A). The treatment 
with hsRANKL and M-CSF led to large multinucleated cells with a smooth periphery lined by 
a band of tightly packed podosomes forming a belt. These podosomes, small cylindrical actin 
structures, showed an increasingly dense phalloidin staining. Furthermore, the podosomes 
were also visualized by Concanavalin A staining showing that the podosomes had bright, 
fluorescent patches that exactly corresponded to the areas bordered by bright lines seen under 
bright-field microscopy (Figure 3.5B). 
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Figure 3.5.: Osteoclast differentiation in cultures stimulated with hsRANKL and M-CSF for 14 days, Phalloidin 
and Concanavalin A staining.  (A) Phalloidin staining of porcine osteoclast showing F-actin rings at the 
periphery of the cells and podosomes. Green: phalloidin; red: propidium iodide (PI) nuclear counterstaining. (B) 
Concanavalin A staining of porcine osteoclast showing glycoprotein containing mannose chains on the 
membrane. Blue: DAPI; green: Concanavalin A. 
 
3.1.4 Morphological characterization of porcine osteoclast generated by 
psRANKL 
To be sure that newly cloned porcine sRANKL is able to induce osteoclasts, the psRANKL 
cDNA was introduced using a transfection method into porcine osteoclastic precursor cells. 
Next, the morphology of the osteoclast formed by psRANKL and M-CSF was compared with 
the morphology of the osteoclast induced by hsRANKL and M-CSF.  
As shown in Figure 3.6A, the osteoclasts´ culture generated by hsRANKL + M-CSF had 
larger osteoclasts, while this generated by psRANKL + M-CSF had small multinucleated cells 
localized within a dense fibroblast/stromal cell layer. Next, both cell cultures were visualized 
by Giemsa and TRACP staining (Figure 3.6B and C), showing bigger osteoclast with highly 
positive TRACP staining for hsRANKL + M-CSF culture, while smaller osteoclasts with low 
TRACP expression for psRANKL + M-CSF culture. Both cultured cell showed 
multinuclearity.  
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Figure 3.6.: Osteoclast differentiation in cultures transfected with psRANKL and stimulated with hsRANKL and 
M-CSF for 7 days, their morphology, Giemsa and TRACP staining. (A) Phase-contrast figure showing typical 
osteoclast morphology. (B) Giemsa staining of porcine osteoclast under light microscopy. (C) TRACP staining 
of porcine osteoclast under light microscopy. The insets show TRACP+ cells in higher magnification. Note the 
multinuclearity of the cells (white arrows). 
 
To visualized podosomes, both cell cultures were stained for Phalloidin and Concanavalin A 
(Figure 3.7A and B). The treatment with hsRANKL + M-CSF led to large multinucleated 
cells with a smooth periphery lined by a band of tightly packed podosomes forming a belt. 
While treatment with psRANKL + M-CSF led to smaller multinucleated cells showing a 
periphery line of podosomes. 
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Figure 3.7.: Phalloidin and Concanavalin A staining of the osteoclasts stimulated by transfected psRANKL and 
by addition of hsRANKL and M-CSF. (A) Phalloidin staining of porcine osteoclast showing F-actin rings at the 
periphery of the cells and podosomes. Green: phalloidin; red: PI. (B) Concanavalin A staining of porcine 
osteoclast showing glycoprotein containing mannose chains on the membrane. Blue: DAPI; green: Concanavalin 
A. 
 
 
3. Results                                                                                                                                     58 
 
3.1.5 In vitro osteoclastogenesis with psRANKL by transfection and bone 
resorption of psRANKL induced osteoclasts 
To continue functional characterization of newly cloned porcine sRANKL, psRANKL was 
expressed in osteoclastic precursor cells by transfection and tested for its ability to induce 
osteoclast formation in vitro. Given that M-CSF is also implicated in osteoclast formation, 
cells cultured only in presence of M-CSF (as a negative control) were used to eliminate any 
possible contamination from M-CSF or endogenous pathway. The cells were also treated with 
hsRANKL + M-CSF (as a positive control) and cultured in medium without any stimulants 
(as a null control).  
To test if the osteoclastic precursor cells are expressing recombinant psRANKL, on day 3 
after transfection, sRANKL ELISA was preformed. The ELISA showed a significant over-
expression of psRANKL of about 92 pg/ml in transfected cells compared to the cells cultured 
in presence with M-CSF which showed very low detectable level of expression (Figure 3.8A).  
After 7 days of incubation, the osteoclastic precursor cells were stained for TRACP. As 
shown in Figure 3.8B, the cytochemistral analysis revealed that transfection of osteoclastic 
precursor cells with psRANKL had the ability to induce the formation of TRACP+ 
multinuclear cells. M-CSF alone had lesser degree of osteoclast inductivity, whereas 
hsRANKL + M-CSF had the strong effect on osteoclast inductivity. No TRACP+ cells were 
observed in cultures when porcine osteoclastic precursor cells were cultured in medium. 
These results indicate that the recombinant psRANKL is a functional protein. The numbers of 
TRACP+ multinuclear cells were scored using light microscopy. As shown in Figure 3.8C, 
introduction of psRANKL induced osteoclasts. The average number of cells per 6-well in the 
presence of hsRANKL + M-CSF was 25,50, transfected with psRANKL + M-CSF 22,25, in 
the presence of M-CSF 8 and in medium 1,25, respectively. These results confirm that 
recombinant psRANKL is able to induce osteoclast in greater number than M-CSF alone. 
Next, these cells were tested for expression of the carbonic anhydrase type II (CA-II), another 
osteoclastic marker that is related to the bone resorbing ability of osteoclasts. Cultures treated 
with hsRANKL + M-CSF or transfected with psRANKL showed a strong expression of CA-II 
in RT-PCR. In contrast, M-CSF alone exhibited significaly lower expression levels of CA-II. 
No basal expression of CA-II was found in cultures incubated with medium alone (Figure 
3.8D).  
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Figure 3.8.: Effects of extracellular domain of psRANKL protein on osteoclastogenesis. Osteoclastic precursor 
cells were transfected with psRANKL expression plasmid. The untransfected or transfected cells were untreated 
or treated with hsRANKL + M-CSF and M-CSF alone, respectively and cultured for 3 or 7 days. (A) sRANKL 
ELISA on day 3 after transfection showing over-expression of psRANKL from transfected cells compared to the 
untransfected cells cultured in presence with M-CSF alone. (B) Osteoclast began to form at day 3 and the 
cultures were stained for TRACP activity at day 7. A strong TRACP signal was observed in osteoclast cultured 
in presence of hsRANKL + M-CSF and transfected with psRANKL, compared to lesser or no TRACP+ cell 
cultures with M-CSF or media, respectively. A close-up view of TRACP+ cells with several nuclei (black 
3. Results                                                                                                                                     60 
 
arrows) is shown. (C) Total number of TRACP+ multinucleated cells was scored after 7 days of incubation. In 
the cultures treated with hsRANKL + M-CSF and transfected with psRANKL, the higher number of osteoclast 
was found whereas the less or very low number was found in cultured treated with M-CSF or medium alone, 
respectively. (D) RT-PCR analysis of CA-II in osteoclasts after 7 days of incubation. Total cellular RNA was 
extracted from cells cultured in media alone or in media supplemented with M-CSF, hsRANKL + M-CSF and 
psRANKL + M-CSF and RT-PCR was performed using CA-II-specific primers. The signal could be detected in 
cultures treated with hsRANKL + M-CSF, psRANKL + M-CSF, and M-CSF alone, while no signal could be 
found in cultures cultured in medium. (E) Bone resorption assay. Untransfected and transfected precursor cells 
were plated on bone slices and cultures were untreated or treated with hsRANKL + M-CSF and M-CSF alone for 
3 days. After osteoclast formed, the level of calcium released was measured showing that osteoclast cultured 
with hsRANKL + M-CSF and psRANKL + M-CSF were able to resorb bone, while that cultured in medium or 
with M-CSF alone were not able. 
 
To determinate the biological effects of psRANKL, osteoclastic precursor cells were plated on 
bone plate and transfected with recombinant psRANKL. After 3 days, the supernatant was 
taken for the measurement of calcium levels by CalciFluor assay as a measurement of 
osteoclast activity (Figure 3.8E). psRANKL increased calcium level (from 0.1 mM to 0.7 
mM) compared to cells cultured in presence with M-CSF alone. These results indicated that 
the cloned region is functionally active and generates bone-resorbing osteoclasts.  
 
3.2 GENERATION OF DOUBLE-TRANSGENIC rtTA-psRANKL PIGS 
3.2.1 Establishment of an inducible Tet-On system 
A tandem construct containing rtTA under the control of CMV promoter and psRANKL 
under the tetracycline regulated promoter was cloned. To obtain such construct, first, the 
target-specific cDNAs were cloned in pLenti6/V5-rtTA-psRANKL (Bla) plasmid by ligation 
reaction. Next, the Blasticidin selection marker from pLenti6/V5-rtTA-psRANKL (Bla) 
plasmid was exchanged with floxed Neomycin resistance gene from lox2Neo plasmid (Figure 
3.9A). To verify the cloning strategy, a digestion analysis of pLenti6/V5-rtTA-psRANKL 
(Neo) was performed by cutting out the insert from the backbone (Figure 3.9B). The correct 
clone was also sequenced to verify the quality of the rtTA, TRE and psRANKL sequences. 
Finally, the plasmid pLenti6/V5-rtTA-psRANKL (Neo) was linearized by PvuI digestion. 
This linearized fragment, having the proper digestion pattern and correct sequence was used 
for the next step – electroporation into porcine fetal fibroblast.  
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Figure 3.9.: Establishment of inducible system, its cloning and functional analysis. (A) A schematic 
representation of the cloning steps of pLenti6/V5-rtTA-psRANKL (Neo) plasmid. (B) Digestion results of 
pLenti6/V5-rtTA-psRANKL (Neo) plasmid with different restriction enzymes showing correct digestion pattern.  
(C) sRANKL ELISA. 293FT cells were transfected with linearized pLenti6/V5-rtTA-psRANKL (Neo) plasmid 
and stimulated or unstimulated with Doxycycline. After 3 days of stimulation, supernatants from stimulated and 
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unstimuled cells were collected and used to assay psRANKL induction. The induction of psRANKL was found 
in transfected and stimulated cells compared to unstimuled ones. 
 
To verify if the pLenti6/V5-rtTA-psRANKL (Neo) plasmid is inducible, the 293FT cells were 
transfected and stimulated with Doxycycline for 3 days. A sRANKL ELISA of supernatant 
from transfected cell stimulated and unstimulated, respectively, was performed. The result 
showed high inducibility of the psRANKL upon stimulation with Doxycycline and no 
background signal without stimulant (Figure 3.9C). 
 
3.2.2 Molecular characterization of double-transgenic porcine fetuses 
With the goal to generate transgenic pigs, the pFFs were electroporated with pLenti6/V5-
rtTA-psRANKL (Neo) plasmid, which were finally used for nuclear transfer. After embryo 
transfer and 40 days of gestation, 3 porcine fetuses were obtained (Figure 3.10A). All fetuses 
had good organ developed according to the period of gestation. 
When DNA was isolated from ear fibroblast from all three fetuses and hybridized with 
radiolabeled rtTA and psRANKL DNA, hybridizing bands were seen, demonstrating the 
presence of genes in two transgenic animals, fetus 2 and 3. Fetus 1 didn’t show the integration 
of the rtTA or/and psRANKL into its genome (Figure 3.10B). In this respect, the fetus 1 is 
used as isogenetic control for further experiments. To compare which one of the two 
transgenic fetuses are expressing rtTA and psRANKL at higher level, the ear fibroblasts and 
tissues like heart, liver, brain and bone, were used for further characterization on mRNA and 
protein level (only cells).  
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Figure 3.10.: Molecular characterization of double transgenic rtTA-psRANKL porcine fetuses 1, 2 and 3 on 
genomic and mRNA level. (A) Figure showing three obtained fetuses at 40 days of gestation. Figures were 
kindly provided by Eleonore Schilling (Institute of molecular animal breeding and biotechnology, Prof. Eckhard 
Wolf). (B) Genomic analysis of the ear fibroblast isolated from three fetuses. Fetus 2 and 3 are transgenic for 
both genes while fetus 1 in not transgenic. Figure is kindly provided by Nikolai Klymiuk (Institute of molecular 
animal breeding and biotechnology, Prof. Eckhard Wolf). (C) RT-PCR analysis of rtTA mRNA from ear 
fibroblast from all three fetuses. PCR results showed an over-expression of rtTA mRNA in fetus 2 and 3 but not 
in fetus 1. (D) RT-PCR analysis of psRANKL mRNA from ear fibroblast from all three fetuses after 
Doxycycline stimulation. No psRANKL expression was found in cell from fetus 1 and 2, while fetus 3 showed 
induction psRANKL mRNA. (E) RT-PCR analysis of rtTA expression in heart, liver, brain and bone isolated 
from three fetuses. No rtTA expression was found in any organs from fetus 1, while fetus 2 and 3 showed lower 
expression of rtTA in heart and liver and higher expression in brain and bone. In (C), (D) and (E) –RT is 
indicating a PCR performed on RNA probes to exclude the potential contamination from cloned cDNA 
sequence. 
 
Using mRNA isolated from ear fibroblast, the rtTA expression was verified. As expected 
fetus 1 didn’t show any expression of rtTA mRNA, the fetus 2 showed weak rtTA expression, 
while fetus 3 showed stronger expression of rtTA (Figure 3.10C). No contamination of cDNA 
was evident in all probes. To test the inducibility of the psRANKL mRNA, the ear fibroblasts 
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were stimulated with Doxycycline for 3 days. This experiment showed that only the fetus 3 
has an expression of psRANKL mRNA in uninduced and induced state (Figure 3.10D). In 
both transgenic fetuses the expression of rtTA on mRNA in different tissues was detectable 
while as expected fetus 1 didn’t show any signal of expression (Figure 3.10E). The expression 
was stronger in brain and bone and weaker in heart and liver from both transgenic fetuses. 
These results are summarized in table 3.1. 
  rtTA psRANKL 
pFF - - 
pFF + Doxy n.d. - 
Heart - n.d. 
Liver - n.d. 
Brain - n.d. 
FETUS 1 
Bone - n.d. 
pFF + - 
pFF + Doxy n.d. - 
Heart + n.d. 
Liver + n.d. 
Brain ++ n.d. 
FETUS 2 
Bone ++ n.d. 
pFF ++ ++ 
pFF + Doxy n.d. ++ 
Heart + n.d. 
Liver + n.d. 
Brain ++ n.d. 
FETUS 3 
Bone ++ n.d. 
Table 3.1.: Summary of expressional results of double transgenic rtTA-psRANKL porcine fetuses 1, 2 and 3 on 
mRNA level. -: no expression; +: good expression; ++: strong expression; n.d.: not determinated. 
 
The expression of rtTA in the cells was also analyzed on protein level by two immunostaining 
procedures. Immunofluorescence staining as well DAB-staining showed low rtTA expression 
in ear fibroblast of fetus 2 and high expression in fetus 3, while no expression in fetus 1 
(Figure 3.11 A and B). 
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Figure 3.11.: Immunocytochemistral analysis of over-expression of rtTA protein in the fibroblasts of three 
fetuses. (A) Immunofluorescence staining of the cells. The negative controls without primary anti-rtTA-antibody 
and the pFF 1 show hardly fluorescence signal. A strong Alexa Fluor 488 signal (green) in two transgenic pFFs 
indicates an expression of rtTA. Green: rtTA staining; blue: DAPI. (B) DAB-immunostaining of the cells. A 
strong positive signal indicated by the brown color was detected in pFF 3 cells, low signal in pFF 2, while there 
was very low background signal in pFF 1 cells.  
  
3.2.3 Generation of double transgenic piglets from the cells isolated from 
fetus 3 
The ear fibroblasts from the fetus 3 were further used for a re-cloning of the animals, i.e. in a 
new nuclear and embryo transfer, wherefrom, 2 piglets (piglets 9878 and 9879) were 
originated. Unfortunately, both piglets were born dead (Figure 3.12A). From the piglet 9878, 
ear fibroblast and bone marrow cells (pBM) could be isolated, while from the piglet 9879 
only bone marrow cells (Figure 3.12B). These cells and tissues (heart, lung, spleen, liver, 
kidney, muscle, tail and skin) were used for further expressional analysis. 
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Figure 3.12.: Piglets 9878 and 9879 and isolated cells from these piglets. (A) Figure showing piglets 9878 and 
9879 after birth. Both piglets were born. Figures are kindly provided by Eleonore Schilling (Institute of 
molecular animal breeding and biotechnology, Prof. Eckhard Wolf). (B) Isolated cells from both piglets. From 
piglet 9878 bone marrow and ear fibroblast could be isolated, while from piglet 9879 only bone marrow cells.  
 
3.2.4 Molecular characterization of double transgenic piglets 9878 and 9879 
originated from fetus 3 
Expression analysis started with RNA isolation from different tissues from both piglets. As 
shown in Figure 3.13A, the RNA quality was good for lung and spleen of both fetuses 
showing the 2 bands of 18 and 26S. While the RNA isolated from heart, liver, kidney, muscle, 
tail and skin from both piglets was degraded. 
Nevertheless, rtTA RT-PCR and RNA-control PCR on tissues from both piglets were 
performed (Figure 3.13B). Even though, the rtTA over-expression could be proved in all 
tissues from both fetuses compared to the wild type animal, the rtTA could be also seen in a 
RNA control PCR, demonstrating cDNA contamination in RNA probes. 
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Figure 3.13.: Molecular characterization of double transgenic rtTA-psRANKL porcine fetuses 9878 and 9879 ´s 
tissues on mRNA level. (A) RNA quality control gel showing good RNA quality from lung and spleen from both 
piglets and degraded RNA from heart, liver, kidney, muscle, tail and skin of both piglets.  (B) RT-PCR and 
RNA-control-PCR analysis of rtTA expression in heart, lung, spleen, liver, kidney, muscle, tail and skin isolated 
from two piglets. Since there was also a band in the without reverse transcription PCR, genomic DNA 
contamination could not be excluded. 
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To avoid the problem of the contaminated RNA, the RNA was isolated from the cell culture. 
The isolation of RNA from ear fibroblast and bone marrow cell showed good RNA quality. 
Next, the cells from both piglets were stimulated with Doxycycline for 3 days and tested for 
rtTA and psRANKL expression. rtTA RT-PCR showed a clearly over-expression of the 
transactivator in each cell type, showing stronger expression in pBM-9879 and weaker in 
pBM-9878 and pEF-9878. No cDNA contamination was obvious. The induction of the 
psRANKL mRNA can be shown only in the pEF-9878, while pEF-9879 and pBM-9878 
didn’t show any psRANKL mRNA induction, rather basal psRANKL expression. In this case 
also the cDNA contamination could not be demonstrated (Figure 3.14). 
 
Figure 3.14.: Molecular characterization of double transgenic rtTA-psRANKL porcine fetuses 9878 and 9879´s 
cells on mRNA level. RT-PCR and RNA-control-PCR (-RT) analysis of rtTA and psRANKL expression in 
isolated cells from two piglets. Both piglets showed over-expression of rtTA in every cell analyzed. The rtTA 
band could not be seen in RNA-control-PCR. After 3 days of Doxycycline stimulation, the induction of the 
psRANKL mRNA could be showed only in the pEF-9878, while pEF-9879 and pBM-9878 didn’t show any 
psRANKL mRNA induction. No cDNA contamination could be demonstrated. 
 
3.3 GENERATION OF rtTA TRANSGENIC PIGS AND KIDNEY CELL 
LINE FROM rtTA-PIGLET 9894 
Initially, the expression vector CAG-rtTA (Supplementary figure 6) was cloned containing 
rtTA cDNA under the control of constitutive chicken β-actin promoter. Another characteristic 
of this vector is the floxed and removable Neomycin resistance cassette, meaning that after 
the electroporation and selection over 2 passages, a stable transfected cell clone could be 
obtained. Cloning of this plasmid was performed by Nikolai Klymiuk (Institute of molecular 
animal breeding and biotechnology, Prof. Eckhard Wolf). 
After electroporation of the porcine fetal fibroblast with the CAG-rtTA vector, the cells were 
selected using Neomycin and used for nuclear and embryo transfer. After the pregnancy of 
117 days, 5 piglets (piglet 9890, 9891, 9892, 9894 and 9895) were born (Figure 3.15A). The 
piglet 9890 died soon after the birth. Piglet 9894 was euthanized within the second day due to 
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poor vitality, but a full set of tissue samples was preserved. The remaining three piglets 
(piglet 9891, 9892 and 9895, Figure 3.15B) were clinically healthy and developed normally 
but were euthanized at the age of 4 weeks to preserve a comprehensive set of tissues (heart, 
lung, spleen, live, kidney, muscle and skin) for genotyping as well as for transgene expression 
studies on the RNA and protein level. In addition primary cell cultures were established from 
the kidneys to serve as nuclear donor cells for second round SCNT experiments. 
 
Figure 3.15.: rtTA-transgenic piglets. (A) Figure showing 5 living piglets 9890, 9891, 9892, 9894 and 9895 after 
birth. (B) Piglets 9891, 9892 and 9895 were sacrificed 28 days after the birth. Both figures are kindly provided 
by Eleonore Schilling (Institute of molecular animal breeding and biotechnology, Prof. Eckhard Wolf). 
 
The expression analysis of the rtTA began with RNA isolation from different tissues of all 
piglets. The quality of RNA was good from all samples (Figure 3.16A). Next, the over-
expression of rtTA on mRNA level was tested in those tissues. RT-PCR analysis revealed 
ubiquitous rtTA-specific RNA expression in all five founder animals. Precisely, in heart, 
liver, kidney, spleen and skin strong differences could have not be seen in expressional 
pattern between the animals, while the piglet 9895 showed lower expression in lung and 
muscle and piglet 9892 in muscle. Appropriate negative controls (wild type animal) gave the 
predicted results, as well as the RNA-control PCR (Figure 3.16B).  
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Figure 3.16.: Molecular characterization of rtTA-transgenic piglets 9890, 9891, 9892, 9894 and 9895´s tissues 
on mRNA level. (A) RNA quality control gel from the tissues showing good RNA quality from all piglets. (B) 
RT-PCR and RNA-control-PCR (-RT) analysis of rtTA expression of obtained organs from five piglets. All 
animals showed over-expression of rtTA in every tissue analyzed. The rtTA band could not be seen in RNA-
control-PCR.  
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To confirm over-expression on a protein level, a Western blot analysis on muscle, liver and 
lung was performed. As evidenced by SDS-PAGE, piglet 9890 and 9894 showed a band of 
approximately 27 kDa in muscle (Figure 3.17A), which meets the size of the rtTA protein. All 
animals showed a protein band in liver and only piglet 9891 and 9894 showed it in lung 
(Figure 3.17B and C). The corresponding negative (wild type animal) and positive (pFF-rtTA) 
controls gave predicted results. 
 
Figure 3.17.: Molecular characterization of rtTA-transgenic piglets 9890, 9891, 9892, 9894 and 9895´s tissues 
on protein level. Total protein from each of the transgenic and wild type piglets and rtTA-pFF was used for 
Western blot analysis. A strong expression can be found on protein level in positive control (rtTA-pFF), in 
muscle (A) of piglet 9890 and 9894, in liver (B) of all transgenic animals and in lung (C) of 9891 and 9894 
piglets, while there was no visible expression of rtTA in wild type animal. The blots were stripped and reprobed 
with β-actin to normalize for the amount of loaded protein. 
 
Additionally, the kidney cells from all transgenic piglets were isolated and analysed for rtTA 
over-expression. The RT-PCR analysis showed clearly over-expression of rtTA mRNA in all 
cell lines. No cDNA contamination was present (Figure 3.18A). On protein level, a 
corresponding band of 27 kDa, can be showed in each kidney cells from all piglets, while 
wild type didn’t show any band (Figure 3.18B). 
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Figure 3.18.: Molecular characterization of rtTA-transgenic piglets 9890, 9891, 9892, 9894 and 9895´s kidney 
cells on mRNA and protein level. (A) RT-PCR and RNA-control-PCR (-RT) analysis of rtTA expression of 
isolated kidney cells from five piglets. All animals showed strong over-expression of rtTA in analyzed cells. The 
rtTA band could not be seen in RNA-control-PCR. (B) Total protein from each of the transgenic kidney cells and 
wild type pKC was used for Western blot analysis. A strong expression can be found on protein level in kidney 
cells of all piglets, while there was no visible expression of rtTA in wild type cells. The blots were stripped and 
reprobed with β-actin to normalize for the amount of loaded protein. 
 
3.3.1 Electroporation of kidney cells from rtTA-piglets with TRE-
psRANKL vector and its characterization 
To confirm that rtTA expressed in transgenic pigs is functionally active, primary kidney cells 
from all founders were nucleofected with a TRE-controlled expression vector for porcine 
sRANKL (Supplementary figure 7). The cloning of this vector was performed by Nikolai 
Klymiuk (Institute of molecular animal breeding and biotechnology, Prof. Eckhard Wolf). 
After generation of stable transfected cell clones, cells were exposed to Doxycycline (1 
µg/ml) for 72 h. 
First, the rtTA over-expression was analyzed in kidney cells. The kidney cells from all 
animals showed an over-expression of rtTA on mRNA level. Next, the induction of 
psRANKL expression was analyzed and the RT-PCR showed an induction of psRANKL in 
kidney cells from piglet 9890 and 9894, even though the kidney cells from piglet 9894 
showed stronger induction then the cells from 9890 piglet. Both porcine cell lines didn’t show 
any basal expression. The cells from piglet 9891, 9892 and 9895 didn’t show an induction or 
basal expression of psRANKL mRNA. No cDNA contamination could be demonstrated in 
each kidney cells (Figure 3.19A). To confirm these results, the Western blot analysis was 
performed using kidney cells and supernatant. As shown in Figure 3.19B, an induction of 
psRANKL can be seen in cells from piglet 9890, 9891 and 9894, while only in the 
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supernatant from piglet 9894 the rtTA protein band can be seen. The cells from piglet 9892 
and 9895 didn’t show an inducibility of psRANKL protein. Finally, culture supernatants were 
harvested before and after Doxycycline stimulation and analyzed by specific ELISA for the 
presence of sRANKL. Non-stimulated TRE-psRANKL nucleofected cells from rtTA 
transgenic founders did not secrete detectable amounts of sRANKL into the culture medium, 
however, a marked increase in sRANKL secretion was observed after Doxycycline 
stimulation of cells from founders 9890, 9891 and 9894 (Figure 3.19C). 
3. Results                                                                                                                                     74 
 
 
Figure 3.19.: Molecular characterization of rtTA-transgenic piglets 9890, 9891, 9892, 9894 and 9895´s kidney 
cells electroporated with TRE-psRANKL construct on mRNA and protein level. (A) RT-PCR and RNA-control-
PCR (-RT) analysis of rtTA and psRANKL expression of isolated kidney cells from five piglets and 
subsequently electroporated with TRE-psRANKL vector. All cell lines showed strong over-expression of rtTA. 
The psRANKL RT-PCR showed an induction of psRANKL upon Doxycycline stimulation in kidney cells from 
piglet 9890 and 9894. Both porcine cell lines didn’t show any basal expression. The cells from piglet 9891, 9892 
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and 9895 didn’t show an induction or basal expression of psRANKL mRNA. The rtTA and psRANKL band can 
not be seen in RNA-control-PCR. (B) Total protein and supernatant from isolated kidney cells from five piglets 
and subsequently electroporated with TRE-psRANKL vector, wild type and psRANKL-pFF was used for 
Western blot analysis upon Doxycycline stimulation. An induction of psRANKL can be seen in cells from piglet 
9890, 9891 and 9894, while only in the supernatant from piglet 9894 the rtTA protein band can be seen. The 
cells from piglet 9892 and 9895 didn’t show an inducibility of psRANKL protein. The blots were stripped and 
reprobed with β-actin to normalize for the amount of loaded protein. (C) sRANKL ELISA of the supernatant 
collected from isolated kidney cells from five piglets and subsequently electroporated with TRE-psRANKL 
vector upon Doxycycline stimulation for 3 days. A strong secretion can be found in kidney cells of piglet 9894, 
9891 and 9892 while in all other cells was no secretion of psRANKL. 
 
3.4 GENERATION OF rtTA-psRANKL TRANSGENIC PIGS 
Based on the results obtained above, the kidney cells from rtTA-TRE-psRANKL-piglet 9894 
were then used for SCNT. After the pregnancy, 4 piglets were born, piglets 9958, 9959, 9961 
and 9962. The piglets 9958 was born dead, piglet 9962 died 2 days after the birth (Figure 
3.20A), while piglets 9959 and 9961 are still alive (Figure 3.20B). From all piglets the ear 
fibroblasts were isolated (Figure 3.20C) and used for expression analysis. 
 
Figure 3.20.: rtTA-psRANKL transgenic piglets after birth and their cells. (A) In this figure, 2 dead piglets 9958 
and 9962 are shown after birth. Figure is kindly provided by Eleonore Schilling (Institute of molecular animal 
breeding and biotechnology, Prof. Eckhard Wolf). (B) Figure showing 2 live piglets 9959 and 9961. Figure is 
kindly provided by Eleonore Schilling (Institute of molecular animal breeding and biotechnology, Prof. Eckhard 
Wolf). (C) Isolated ear fibroblasts from four piglets. 
 
The ear fibroblasts isolated from four obtained piglets were used for expressional analysis. 
First, to test if the TRE-psRANKL construct was integrated into the genome, the ear 
fibroblasts were used in genomic PCR analysis which showed that piglets 9958, 9961 and 
9962 were transgenic for psRANKL, while piglet 9959 not (Figure 3.21A). Next, the cells 
were used in a rtTA RT-PCR that showed that cells from all piglets are over-expressing 
transactivator (Figure 3.21B). No cDNA contamination can be demonstrated. Furthermore, 
the cells were stimulated with Doxycycline for 3 days to test the induction of psRANKL and 
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analyzed with PCR and Western blot. Unfortunately, no psRANKL induction could be seen 
on mRNA level as well as on protein level (Figure 3.21B and C). 
 
Figure 3.21.: Molecular characterization of rtTA-psRANKL-transgenic piglets 9958, 9959, 9961 and 9962´s ear 
fibroblasts on genomic, mRNA and protein level. (A) Genomic PCR of the ear fibroblast isolated from four 
piglets. Piglets 9958, 9961 and 9962 are transgenic for psRANKL gene, while piglet 9959 is not transgenic. The 
figure is kindly provided by Nikolai Klymiuk (Institute of molecular animal breeding and biotechnology, Prof. 
Eckhard Wolf). (B) RT-PCR and RNA-control-PCR analysis of rtTA and psRANKL expression of isolated ear 
fibroblasts from four piglets. All animals showed strong over-expression of rtTA in analyzed cells. The 
psRANKL RT-PCR didn’t show an induction of psRANKL upon Doxycycline stimulation in the cells from all 
piglets. No psRANKL basal expression can be shown in all piglets. The rtTA and psRANKL band can not be 
seen in RNA-control-PCR. (C) Total protein from isolated cells from four piglets, wild type and psRANKL-pFF 
was used for Western blot analysis upon Doxycycline stimulation. An induction of psRANKL can not be seen in 
any cells. The cells from piglets 9961 and 9962 are showing basal psRANKL protein expression as seen in a 
wild type cells. The blots were stripped and reprobed with β-actin to normalize for the amount of loaded protein. 
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3.4.1 In vivo Doxycycline stimulation of piglets 9959 and 9961 
The surviving founder animals 9959 (control, only rtTA transgene) and 9961 (rtTA and 
psRANKL transgenes) were examined for induction of the transgene in vivo. A first 
Doxycyline stimulation experiment was performed at age of 10 weeks with a dose of 3.2 and 
6.3 mg/kg body weight for 10 days in transgenic boar 9961 and a wild-type control 9959. The 
induction of RANKL was investigated in animals at day 0, 3, 6 and 10, using ELISA for 
sRANKL, while bone resorption was studied by ELISA for Cathepsin K and Crosslaps. 
As showed in Figure 3.22A, systematic application of Doxycycline was able to increase 
significantly psRANKL plasma levels in double transgenic piglet 9961, while control piglet 
9959 didn’t show an induction of psRANKL during stimulation. This increase of circulating 
psRANKL was already seen 3 days after onset of stimulation. When the Doxycycline 
concentration was doubled, the concentration of psRANKL was also doubled. Interestingly, 
increased plasma levels of psRANKL were followed by an increase in serum Cathepsin K 
concentrations, a marker of stimulated osteoclast activity (Figure 3.22B). This level of 
Cathepsin K in the transgenic piglet 9961 is decreasing with increasing Doxycycline 
concentration, while the level in the control animal 9959 remained at the same level during 
the whole experimental period. The expression of CTX did not show differences in two 
animals (Figure 3.22C). 
For determination of dose-dependent psRANKL induction, we started a second stimulation 
experiment in 5-month-old animals, using four different doses of Doxycyline (6.3, 12.5, 25 
and 50 mg/kg body weight per day) for 10 days each in 9961 piglet and a wild-type control. 
Blood samples were taken from the jugular vein at day 3, 6 and 10 for each dose of 
Doxycycline and RANKL concentrations in plasma were quantified by specific ELISA. A 
Doxy dose-dependent increase in RANKL concentration in plasma up to >150 pg/ml was 
revealed for the transgenic pig, whereas plasma RANKL concentrations in the equally treated 
control pig ranged around the detection limit of the ELISA (Figure 3.23A). As the ELISA was 
not able to discriminate between transgenic and endogenous RANKL, we tested the 
concentration of the protein in plasma from 10 wild-type pigs of similar age. In all samples 
RANKL concentrations were around the detection limit of the ELISA (Figure 3.23B). 
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Figure 3.22.: Molecular characterization of resorption markers in two piglets 9959 and 9961 after Doxycycline 
stimulation for 0, 3, 6 and 10 days with 2 different Doxy concentrations, 0,25X and 0,5X (see Application of 
Doxycycline). (A) sRANKL ELISA of the plasma collected from transgenic 9961 and control 9959 piglets after 
Doxycycline stimulation for 0, 3, 6 and 10 days. A strong secretion can be found in piglet 9961 starting from day 
3 and increasing, while in piglet 9959 no secretion of psRANKL was found. (B) Cathepsin K ELISA of the 
plasma collected from transgenic 9961 and control 9959 piglets after Doxycycline stimulation for 0, 3, 6 and 10 
days. A significantly higher release of Cathepsin K can be found in piglet 9961 from day 6, while the level of 
Cathepsin K in the control animal 9959 remained at the same level during the experimental time. (C) CTX 
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ELISA of the serum collected from transgenic 9961 and control 9959 piglets after Doxycycline stimulation for 0, 
3, 6 and  10 days. No obvious expressional pattern could be seen in both animals. 
 
 
Figure 3.23.: Dose dependence characterization of psRANKL in two piglets 9959 and 9961 after Doxycycline 
stimulation for 0, 3, 6 and 10 days. 0,5X, 1X, 2X and 4X are indicating different concentration of Doxy (see 
Application of Doxycycline). (A) sRANKL ELISA of the plasma collected from transgenic 9961 and control 
9959 piglets after Doxycycline stimulation for 0, 3, 6 and 10 days. A strong secretion can be found in piglet 9961 
starting from day 3, increasing at day 6 and decreasing at day 10, while in piglet 9959 no secretion of psRANKL 
was found. The same pattern of secretion can be found in all dose of Doxy used. (B) sRANKL ELISA in plasma 
collected from 10 different wild type pigs. Low basal RANKL expression could be detected in 6 wild type pigs. 
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4. DISCUSSION 
Understanding the bone biology is important for the development of a successful treatment of 
bone diseases, such as osteoporosis. Literature shows that cytokines and their signalling 
pathways, like RANK/RANKL/OPG, play an essential role in the regulation of normal bone 
remodelling [171]. Alteration in this system causes an imbalance between bone resorption and 
bone formation. RANKL is thought to play a crucial role in the development of post-
menopausal osteoporosis [172]. In addition, the clinical relevance of RANKL is also 
supported by the finding that blocking RANKL by an inhibitory antibody (Denosumab) 
prevents osteoporosis and fractures in postmenopausal women [173]. Understanding the 
specific role of RANKL in bone biology is thus essential for understanding the disease 
mechanisms and important for developing new therapeutic strategies [174]. Therefore, in this 
thesis, the specific cytokine pathway of RANKL was studied. For practical reasons rodent 
models have been used most frequently in medical research. Nevertheless, the porcine bone 
anatomy and physiology is related much closer to humans. Therefore, porcine animal models 
would be more suitable for studying bone physiology and diseases in vivo [143,175]. For this 
purpose we used Sus scrofa (pig) as a large animal model, in which we expressed a soluble 
RANKL under the Tet-On regulation. Having this large animal model system will help us to 
better understand the development of the osteoporosis. In addition, this is the first genetic 
large animal model for osteoporosis with regulated gene expression.  
 
4.1 OVER-EXPRESSION AND FUNCIONALTY OF THE 
EXTRACELLULAR DOMAIN OF PORCINE sRANKL 
4.1.1 Sequence analysis suggests that sRANKLs are conserved 
Initially, RANKL was considered to be a membrane-bound protein and required a cell to cell 
contact for fulfilling its biological roles [58,61,62,93,176]. A decade ago, a study by Lum et 
al. [177] has shown that mouse RANKL, like TNF- , can be shed by the metalloprotease 
disintegrin TACE. As a result, the soluble RANKL form is released into the circulation with a 
potent effect on osteoclastogenesis. Our initial goal was to produce a functional porcine 
extracellular domain of RANKL (sRANKL) with high level of secretion. Therefore, taking 
into account the results of Lum et al. [177], we cloned the porcine sRANKL without the N-
terminal transmembrane domain. Instead, we added an N-terminal Igκ-leader sequence to 
facilitate the secretion of the new fusion protein.  
Next, by the use of human RANKL-specific primers, we were able to amplify a part of the 
porcine gene. The sequence analysis showed a considerable nucleotide homology to human, 
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murine and rat sequences, suggesting that this gene is highly conserved between species. 
Indeed, within the phylogenetic tree created, the porcine sRANKL is evolutionary closer to 
the human. Even though, pigs are evolutionary distinct from primates and rodents, they are 
closer related to humans than to mice and rats. Because of this relationship, pigs have already 
shown a very high anatomical, physiological, metabolic and pathological similarity to humans 
[178,179]. So, because of its proximity to the humans we found that using Sus scrofa as a 
large animal model to analyze the osteoporotic progression is more suitable approach.  
Already cloned RANKL proteins are considered to be type II transmembrane glycoprotein 
belonging to the TNF superfamily. The ligands of the TNF superfamily are characterized by a 
conserved C-terminal domain called the TNF homology domain (THD) [101]. This domain is 
responsible for the formation of functional homotrimer and for the specific receptor binding. 
Despite their varied actions, members of the TNF ligand and receptor families have 
remarkably similar structures and their mode of interaction is conserved. Indeed, alignment of 
porcine with human, mouse and rat sRANKL revealed nearly identical amino acid sequence 
within the THD domain, suggesting that this domain is highly conserved [180]. The 
homology of the glycosylated site within THD domain was also conserved in all four aligned 
sequences. Therefore, the homology of the sequence suggests that newly cloned porcine 
sRANKL belongs to the TNF superfamily. Consistent with this observation, one could 
conclude that porcine sRANKL will have a similar role like other ligands of the TNF 
superfamily. In general, the ligands of the TNF superfamily have pivotal roles in the 
organization and function of the immune system [181,182], which was an evolutionary 
advancement in vertebrate. In addition, RANKL and its receptor RANK have not got a critical 
function in bone homeostasis, but they are also important in the terminal differentiation of the 
lactating mammary gland [183]. 
 
4.1.2 Lentiviral gene transfer successfully over-expresses porcine sRANKL 
at a high level 
In order to achieve an over-expression in the cells, few techniques can be employed. Each of 
them has its advantages and drawbacks. For initial screening and analysis the cell transfection 
can be used, as it provides excellent modulation efficiency. The major disadvantage of this 
system is it very low integration chance. Next, stable transduction can be achieved by the use 
of different virus based technologies – retroviral, adeno-associated viruses (AAV) and 
lentiviral. Bosch et al. [184] showed that transduction with adeno-associated viruses had a 
higher transfection efficiency when compared to nonintegrating plasmids, in porcine 
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mesenchymal stem cells and skin fibroblasts. Nevertheless, retro- and AAV viruses have a 
potential mutagenesis risk and in many cases methylation-dependent gene silencing can occur 
[185,186]. Lentiviruses are considered as a promising alternative to the original oncogenic 
retrovirus, because they resist the methylation-dependent gene silencing, have a consistently 
higher transduction rates and stably integrate into the host genome [187]. In the study of 
Ezashi et al. it was shown that porcine fetal fibroblasts can be transduced by the use of a 
lentiviral delivering system [188]. They also showed that these fibroblasts were successfully 
transduced by lentiviruses containing human genes, like OCT4, SOX2, KLF4 and c-MYC, in 
order to generate pluripotent stem cells [188]. Our first observation of the lentiviral 
psRANKL-transduced pFFs showed no visible morphological or proliferation changes in 
comparison to the wild type control. Despite of the guarantee of stable long-term high gene 
expression detected in vitro, eventually in vivo limitations can occur [189]. 
Once we proved that the porcine cells produced increased levels of psRANKL mRNA and 
protein, we next, quantitatively analyzed the porcine sRANKL release in the cell culture 
supernatants, using an ELISA known to detect human sRANKL [190]. Elevated sRANKL-
concentrations have been detected by ELISA in the supernatants of the pig bone marrow 
stromal cells stimulated with 1α2,5(OH)2D3 [190]. Indeed, the sRANKL level was 
significantly higher in cells transduced with porcine sRANKL lentiviruses. Furthermore, a 
light microscopy analysis clearly showed that psRANKL was presented in cell cytoplasm, 
most likely in the place of its biosynthesis. Additionally, with the cytoplasm staining, we also 
detected psRANKL along the plasma membrane of the porcine sRANKL-pFF.  
Taken together, we can conclude that using a lentiviral delivery system leads to a significant 
increase in the expression and production of active psRANKL.  
 
4.1.3 Porcine osteoclasts generated by human sRANKL show typical 
osteoclast morphology 
Osteoclasts are one of the key cells responsible for the bone remodelling. Unfortunately, it is 
very difficult to access osteoclasts. This is mainly due to two properties of these cells. First, 
under physiologic conditions, the osteoclast is a very scarce cell type, covering only 1% of the 
bone surface [192]. Second, calcified tissue is hard to handle, which makes it nearly 
impossible to purify satisfying numbers of authentic cells for in vitro studies. Thus, it is 
important to establish a system for generating of homogeneous osteoclast cultures [193-195]. 
However, human osteoclasts are currently generated by isolation of primary bone marrow 
cells that are adherent and lacking in nonadherent lymphoid cells. Stimulation of this mixed 
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population with M-CSF and sRANKL drives a proportion of these precursors to the 
monocyte-macrophage lineage and subsequently to mature osteoclasts [58,62,95,196].  
Here, for the first time the ability of human soluble RANKL, together with human M-CSF, 
was demonstrated to induce osteoclastogenesis in porcine bone marrow-derived cells in vitro. 
The generated cells show the characteristics of osteoclasts: they were multinucleated and 
showed the typical cytoskeletal structures like the formation of actin rings and podosomes. 
Furthermore, they expressed molecular markers characteristic of osteoclast differentiation, 
like tartrate-resistant acid phosphatase (TRACP). Moreover, the morphology of the generated 
cells is consistent with human osteoclast morphology [197].  
It is known that the cytoskeletal organization in porcine bone marrow-derived cells changes 
markedly during the differentiation into the osteoclast [198]. In this study, actin ring 
morphology was observed in primary porcine osteoclast cultures after treatment with a human 
sRANKL and M-CSF. Phalloidin and Concanavalin A staining showed that actin ring 
structures became dispersed already after treatment.  
 
4.1.4 Porcine sRANKL generates osteoclasts with osteoclastic activity 
After successful osteoclastogenesis of porcine bone marrow with human sRANKL and M-
CSF, an in vitro differentiation study with porcine sRANKL was performed. We wanted to 
investigate the functional activity of the newly cloned protein. Therefore, we carried out the 
functional study of porcine sRANKL in a physiological cellular background by using porcine 
primary osteoclast precursor cells.  
As with the human sRANKL, the truncated porcine sRANKL was sufficient to induce 
osteoclastogenesis. Cells transfected with porcine sRANKL generated nearly the same 
number of osteoclasts compared to cells cultivated in the presence of recombinant human 
sRANKL, although the concentration of human sRANKL in the supernatant was nearly 200-
fold higher. When the osteoclastic precursor cells were incubated in a medium (containing 
FBS), only a small number of osteoclasts was counted. This may suggest that the serum 
supports the survival of mature osteoclasts to some degree [199]. 
The morphology of the generated osteoclasts was consistent with typical osteoclast 
morphology. The multinucleated cells display the typical cytoskeletal features like the 
formation of actin rings and the appearance of podosomal attachments. Furthermore, they 
express the specific osteoclastic markers like TRACP and CA-II.  
We used CA-II as an osteoclastic marker. CA-II expression appears at an early stage of 
differentiation on osteoclasts [200]. mRNA for CA-II can be found prior to observing 
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multinucleated osteoclasts, suggesting that CA-II may be present on committed osteoclast 
progenitor [200]. Porcine and human sRANKL induced the expression of the CA-II, but there 
was also lower expression with M-CSF alone. Laitala et al. have shown that CA-II was 
expressed not only in osteoclasts but also in some mononuclear bone-derived cells [200]. A 
distinct group of mononuclear cells expressing CA-II might be the osteoclast precursors. In 
nonresorbing osteoclasts CA-II mRNA levels are low or even below the detection limit. When 
osteoclasts are activated for resorption, a rapid increase in the mRNA levels of CA-II occurs. 
The nonresorbing osteoclasts expressing CA-II mRNA could be starting resorption and 
similarly, osteoclasts associated with a lacuna but not expressing mRNA for CA-II, might just 
have finished bone resorption [200]. Furthermore, it is known that M-CSF is required for 
progenitor cells to differentiate into osteoclasts, but M-CSF on its own cannot complete 
osteoclastogenesis. Fuller and Chambers [201] reported that M-CSF prolonged the survival of 
mature osteoclasts, whereas in the absence of M-CSF, the number of osteoclasts were 
strikingly decreased. Therefore, the fact that we found an expression of the osteoclastic 
marker CA-II and TRACP-positive cells in the presence of only M-CSF, might be due to an 
endogenous RANKL production. Nevertheless, the osteoclasts formed in the presence of M-
CSF alone were significantly less and smaller than with combined treatment with human or 
porcine sRANKL and M-CSF. On the other hand was M-CSF alone not sufficient to produce 
bone-resorbing osteoclasts. Only when porcine or human sRANKL was added, functional 
osteoclasts were generated.    
These results not only reveal that the human sRANKL can differentiate porcine osteoclasts, 
but also indicate that the porcine sRANKL has similar function than the known human 
sRANKL.  
 
4.2 rtTA-psRANKL TRANSGENIC FETUSES GENERATED BY 
ELECTROPORATION OF LENTIVIRAL CONSTRUCT 
4.2.1 Porcine sRANKL is inducible in 293FT cells after Doxycycline 
stimulation in a Tet-On system 
Traditional constitutive over-expression is often limited by its inability to precisely control the 
timing and level of gene expression, which are critical for the function of many genes. It is not 
uncommon for fate-determining genes to be toxic at inappropriate stages or even have 
different or complete opposite functions at different expression levels [202]. Thus, efficient 
conditional manipulation of transgene expression is necessary. The most common strategy to 
achieve conditional transgene expression is the use of the tetracycline-inducible gene 
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expression systems (Tet-Off or Tet-On), which has been extensively used in mammals 
[149,150]. This system utilizes transactivator (rtTA), transactivator responsible element 
(TRE) and a drug Doxycycline. Some major advantages of this system compared to the other 
gene regulation systems (ecdysone-regulated gene switch [203,204], the lac operator–
repressor system [205] and the inducible GAL4/UAS system [206]) are a well-known safety 
profile, easy availability and good tissue penetration of the regulating drug. Moreover, 
bacterial origin of the Tet- elements assures minimal interference with endogenous 
physiological processes of the eukaryotic cells. For all these reasons we have chosen this 
system to obtain a regulated gene expression. Most importantly, the establishment of an 
inducible system was needed, because the constitutive sRANKL expression in a mouse model 
was embryonic lethal [105]. 
Gene transfer vectors derived from lentiviruses are widely used in molecular and cellular 
biology. Those vectors have the unique capacity to transmit one or few copies of a transgene 
into almost every cell type of vertebrates. The transferred genetic information is permanently 
integrated into the host cell chromosome [207]. At the same time, lentiviral vectors have 
emerged as the most efficient and versatile systems for somatic and germ-line gene transfer, 
because of their high transmissibility in quiescent cells [117,208]. In the present study, a 
Doxycycline-controlled system that allowed continuous expression of rtTA protein and 
regulated porcine sRANKL expression was generated. The use of such binary Tet-On system 
in animals usually requires the establishment of two transgenic lines [209,210]. Thus, to 
obtain a double-transgenic offspring the two transgenic lines must be crossed. The 
disadvantage of this approach is the lack of control of the appropriate copy number of either 
the transactivator or the responder line. This may result in an imbalanced expression of the 
transgene [211,212]. To avoid this problem we combined the two expression units of the Tet-
On system on a single DNA fragment. Furthermore, in order to avoid multiple transfections of 
the target cells, which would increase the risk of insertional mutagenesis [2123,214], a single 
lentiviral vector, which delivered the expression cassettes for both, transactivator and 
transgene, was used. Such lentiviral vectors carrying the elements of the Tet system have been 
described but they make use of the Tet-Off system [2145,216]. Thus, we generated the first 
lenviral vector that make a use of the Tet-On system. 
To characterize Doxycycline-regulated transgene expression of our vector, a single construct, 
carrying rtTA and porcine sRANKL as transgenes, was introduced into the cells and the 
expression of the transgene was studied. For this purpose, we used sRANKL ELISA and 
measured the expression of psRANKL upon Doxycycline stimulation. The ELISA showed no 
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signal in OFF state. Our results support the tight control of the gene expression, since, in the 
absence of Doxycycline, the psRANKL expression was at or below the detection level.  
 
4.2.2 Ear fibroblasts of transgenic fetuses generated by electroporation of 
the lentiviral construct express rtTA and induce low porcine sRANKL 
expression upon the Doxycycline stimulation 
In a first attempt to create a transgenic porcine model, a lentiviral gene transfer technology 
was used. This transfer technology had shown to be effective in bovine and porcine animal 
models [217]. In contrast to lentiviral transgenesis, the efficiency of DNA microinjection, the 
most widespread technology to generate transgenic animals [218], is low. In the mouse 
model, approximately 2.6% of the transgenic offspring per injected and transferred embryos, 
can be obtained. In the pig model the efficiency is even lower, ranging at 0.9% [219]. In 
contrast, the generation of transgenic pigs carrying the green fluorescent protein (GFP) gene 
by lentiviral gene transfer revealed 70% of the born animals being transgenic [217]. 
Therefore, lentiviral gene transfer was adapted to pigs and resulted in high proportions of 
transgenic offsprings [217,220].  
When the expression of the rtTA-transgene was analyzed, the results showed that the 
heterologous CMV promoter is sufficient to direct the expression of rtTA
 
mRNA, although 
the expression was variable within cell types and different tissues. This may be explained by 
an inappropriate copy number or restricted tissue specificity of the rtTA as shown in the study 
by Kues et al. [221]. The variable rtTA-expression levels observed within the cell lines and 
tissues may be perhaps attributed to the relative sensibility of the cytotoxic effects of rtTA 
[222].  
Next, the porcine sRANKL mRNA expression upon Doxycycline stimulation was analyzed in 
vitro. A RT-PCR allowed the determination of the background expression of porcine 
sRANKL transgene in the absence of Doxycycline, showing a leakage of transcription from 
the minimal CMV promoter situated in the TRE-regulated promoter. This background 
expression led to a detectable porcine sRANKL activity in fibroblasts of fetus 3. Background 
activity in the OFF state has also been reported when the Doxycycline-regulated expression of 
luciferase was delivered by two lentivirus vectors [212]. This may suggest that the 
background activation of the minimal CMV promoter is due to transactivatory effects of the 
chromosomal environment into which the vector is integrated, or to transactivation by 
enhancer elements within the CMV promoter used to express the transactivator [223]. All 
these parameters could be under the influence of the chromatin status of cis-acting sequences 
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present in the vector (Tet-responsive elements and promoter driving the transcription of 
regulatory gene) and they are therefore dependent on the position of the integrated vector 
DNA in the transfected cell genome. Moreover, the design of such a vector has been difficult 
because of transcriptional interference occurring between the cis-acting sequences within the 
vector [31]. A study by Barde et al. [224] showed that relative orientations of the 
transcriptional cassettes, as well as their spacing within the vector, have an impact on both 
background activity levels and inducibility.   
 
4.2.3 rtTA-psRANKL piglets originated from fetus 3 were born dead and 
their cells did not induce psRANKL 
Since the cells from fetus 3 showed at least a psRANKL expression, they were used for a 
subsequently re-cloning of the animal.  
Unexpectedly, the regulated phenotype resulted in a lethality of the newborns. This finding 
suggests that even a low over-expression of porcine sRANKL in the fetal stage causes the 
prenatal death confirming the results obtained by Mizuno et al. [105]. This is not surprising 
since RANKL is an essential regulator of osteoclastogenesis, lymphocyte development and 
mammary gland development [62,96,107]. Thus, the fetal death may be due to an abnormality 
in bone metabolism or in immune system. 
From both dead animals, the heterogeneous cell population from bone marrow could be 
isolated, showing that cells in the bone are preserved from degradation and environmental 
changes, unlike ear fibroblast. 
Since both animals were born dead, we were not able to establish the time point at which they 
died and the period that was needed for tissue-RNA degradation. For this reasons we 
performed a RNA control PCR that showed cDNA contamination in our RNA preparation, 
further confirming the statement that RNA was degraded already at the beginning of the 
preparation of the sample. Therefore, we can not prove whether the over-expression of rtTA is 
due to the transcriptional over-expression or the cDNA contamination. Thus, in order to avoid 
this problem in the further experiments, good quality RNA was isolated from cells and RT-
PCR showed strong over-expression of rtTA. Furthermore, the psRANKL mRNA expression 
upon Doxycycline stimulation was analyzed. A RANKL-RT-PCR showed a high background 
expression of transgene in OFF state, indicating a leakage of transcription or interaction of the 
two expression cassettes as discussed above. 
The lethal phenotype of this system prevented the study of the contribution of the psRANKL 
in living organism. 
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4.3 rtTA TRANSGENIC PIGS 
Inducible transgene expression is an essential refinement of genetic engineering of large 
animals, particularly for the generation of biomedical models. Many expression regulation 
schemes have been proposed. Most extensively studied are vector systems containing 
promoters that respond to the binding of small molecules such as tetracycline [149] or 
rapamycin [225]. The transgene expression can be controlled through administration of the 
small molecular drugs [150,226]. Indeed, a tetracycline-regulation scheme, Tet-system, has 
been used successfully in numerous transgenic animal models, with a variety of transgenes 
targeted at various tissues and organs [210,227-232]. Nevertheless, the generation of these 
lines is traditionally a difficult task. Several factors are known to influence the efficiency of 
the Tet-system in transgenic animals, with the most important being the site integration of the 
transgene [233]. Moreover, the expressions of therapeutic genes including hGH and M-CSF 
were shown to be effectively controlled with such a Tet-system in vitro [234]. In vivo, Rizzuto 
et al. used a similar vector encoding the erythropoietin gene-transfected mouse muscle by 
electroporation. Erythropoietin expression was shown to be turned on and kept on with daily 
oral Doxycycline administration for 56 days [235]. 
 
4.3.1 rtTA-transgenic piglets express rtTA at high level in cells and organs 
In contrast to a previous approach where the two components of a binary tetracycline-
regulated expression system were combined on a single vector, we used a two-step approach 
and transferred the rtTA and TRE-psRANKL expression cassettes sequentially. This approach 
has a number of advantages: (1) transcriptional interference between adjacent expression 
cassettes [191] is avoided; (2) transgenic pigs with a suitable expression level and pattern of 
rtTA can be used as genetic basis for any TRE-controlled expression cassette; and (3) 
mendelian segregation of the rtTA and TRE-psRANKL expression cassettes generates all 
genetic constellations (non-transgenic, single-transgenic, double-transgenic) required for well-
controlled experiments. Due to the large litter size in pigs all these genetic constellations are 
expected in a single litter. In detailed, this strategy included the cloning of two constructs 
which were introduced step by step to obtain double transgenic pigs. One construct expressed 
rtTA under a strong constitutive promoter and other expressed psRANKL under tetracycline-
inducible promoter. The lentiviral construct was also aborted, since the study of Hofmann et 
al. [189] analyzed an epigenetic regulation of integrants in lentiviral transgenic animals in 
vivo. This study showed that one-third of the proviruses exhibited low or undetectable levels 
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of expression and a high degree of methylation of CpG dinucleotides, reminiscent of gene 
silencing. Furthermore, to generate high levels of rtTA expression, we decided to switch from 
the CMV promoter to the chicken β-actin (CAG) promoter. This idea is supported by previous 
studies in which it was revealed a mosaic expression of β-galactosidase within tissues was 
revealed when rtTA was under the control of a CMV promoter [209], but this problem has not 
occurred before when a strong tissue-specific promoter was used [210]. Moreover, this 
promoter has been used in previous experiments to express human CD59 and DAF in 
transgenic mice and pigs resulting in widespread tissue expressions [236,237]. 
In the first round of electroporation and nuclear transfer, rtTA-transgenic pig lines were 
produced. To select the most suitable rtTA transgenic founders, the animals were euthanized 
and systematically investigated for rtTA-specific RNA and protein expression in multiple 
tissues. These lines showed a strong and nearly ubiquitous expression of rtTA mRNA in the 
organs. However, the presence of rtTA
 
transcripts does not necessarily mean that the rtTA
 
transgene is expressed on the protein level. Unexpectedly, transgenic pigs carrying rtTA 
displayed confined expression in muscle and lung on protein level. These results are 
consistent with previous studies, which showed that transgene expression in transgenic 
animals may be different inbetween different tissues [238,239]. Mosaic expression patterns 
have also been described in Tet-transgenic mice and, in some cases, the highest expression 
levels were found in skeletal muscle [209,240,241], and in Tet-Off transgenic pigs [221]. The 
reason for this mosaic expression pattern could be due to the gene dose effects, which led to 
the widespread expression in transgenic animals. Furthermore, unknown molecular 
mechanisms can result in the observed differential expression in transgenic pigs.  
Nevertheless, when RNA and protein were isolated from kidney cell of rtTA-transgenic lines, 
a strong over-expression of rtTA could be detected on mRNA, as well on protein level, 
confirming that the CAG promoter has an ability to strongly express the desired gene. 
 
4.3.2 rtTA-kidney cells from piglet 9894 electroporated with TRE-
psRANKL show the best induction of psRANKL upon Doxycycline 
stimulation 
To further ensure selection of the best founders, primary kidney cells from each animal were 
nucleofected with TRE-psRANKL expression cassettes, and in vitro Doxy stimulation 
experiments were performed. After nucleofection with the TRE-RANKL cassette, cells from 
the three founders showed low baseline expression, but a high induction of transgene 
expression after stimulation with Dox. These findings demonstrate reliable and reproducible 
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Dox-regulated transgene expression in cell cultures derived from specific rtTA-transgenic 
founders. Why in two of the cell line (pKC-9890, 9891-psRANKL) the induction could be 
seen on protein level but not on mRNA level, is not clear. Furthermore, the psRANKL mRNA 
and protein expression allowed no determination of a background expression signal of the 
transgene in OFF state, showing tight control of the Tet-On system. On the other hand, in two 
cell lines (pKC-9892- and -9895-psRANKL) the expression of psRANKL could not be 
demonstrated on mRNA and protein level in ON state, indicating that these lines probably 
didn’t integrate the TRE-psRANKL vector and thus, weren’t able to express psRANKL. 
Taken together, the best performance showed the cell line derived from the rtTA-piglet 
number 9894 which was electroporated with TRE-psRANKL. Subsequently, this cell line was 
the donor for the next nuclear transfer and led to the birth of double transgenic piglets. 
 
4.4 rtTA-psRANKL DOUBLE TRANSGENIC PIGS 
4.4.1 Ear fibroblasts from rtTA-psRANKL double transgenic piglets 
express rtTA but don’t induce psRANKL upon stimulation 
To test if these in vitro findings predict inducible transgene expression in vivo, we cloned 
double transgenic pigs with TRE-psRANKL on the background of rtTA founder 9894. In 
comparison to the SCNT experiments for generation of the TA transgenic founders, the 
efficiency of SCNT after nucleofection with the TRE-controlled expression vectors and the 
survival of the resulting piglets were poor. This is most likely due to an accumulation of 
epigenetic abnormalities [242] after subsequent rounds of nucleofection, selection and SCNT 
and should be overcome if cells from rtTA transgenic animals propagated by sexual breeding 
are used. Nevertheless, from each combination a viable animal was obtained and inducible 
transgene expression could be tested in vivo.  
After successful nuclear and embryo transfer, four transgenic piglets were created. As 
expected, all four piglets were transgenic for rtTA (data not shown), but only one was not 
transgenic for the psRANKL gene (piglet 9959). This may be due to the selection process of 
the donor cells of the culture after electroporation. Taken together, we were able to obtain 
three double rtTA-psRANKL transgenic animals. 
Even though three of four animals were transgenic for psRANKL gene, none of transgenic 
cells did express psRANKL on mRNA and protein level in OFF or ON state. These findings 
can be related to the transcriptional repression of cellular genes that may be happing and it is 
often associated with a higher frequency of methylated cytosine residues in the 5´ flanking 
DNA, particularly at CpG sites [243,244] or to a low expression level [189]. Two decades 
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ago, Prosch [245] showed that methylation of CpG sites in the CMV promoter abolished 
transcription in transfected cells in a culture. Moreover, methylation was associated with the 
absence of a viral gene expression and it has been suggested that de novo methylation of 
foreign DNA represents a cellular defence mechanism against the transcription of foreign 
genes [246,247]. Furthermore, a negative correlation between methylation of the promoter 
and gene expression has been documented previously [248,249]. Along this line it is 
interesting that the CpG depleted CMV promoter constructs gave rise to a long term 
expression in vivo [250]. Furthermore, it is well known that genomic methylation and histone 
modifications undergo major changes during development [251].  
Additionally, this data could be explained by the fact that the expression was analyzed in ear 
fibroblasts and perhaps an unknown mechanism in porcine ear fibroblasts exists, which 
doesn’t allow the transcription and transduction of the regulated gene. Indeed, a study by 
Kong et al. [252] showed a methylation in ear fibroblasts of transgenic pigs when compared 
to kidney cells. Moreover, an increase in transgene promoter methylation was demonstrated 
during individual development of transgenic pigs and transgenic fibroblast cells [252]. 
Therefore, our data probably indicate that the de novo methylation in ear fibroblast may 
interfere with the proper expression of the tetracycline sensitive promoter. Since we did not 
investigate the silencing effect, we cannot conclude for sure if this is happening in our system. 
Thus, further studies are required to analyze the silencing mechanisms of the exogenous DNA 
in order to understand the repression of the expression. 
 
4.4.2 The rtTA-psRANKL transgenic pig shows upregulation of resorption 
markers 
The major in vivo objective was to determine whether the expression of transgene psRANKL 
contributes to the increased bone resorption in transgenic pig. For this purpose, two resorption 
biochemical markers, Cathepsin K and CTX were chosen. To analyze the psRANKL 
induction upon Doxycycline stimulation, the plasma RANKL levels were evaluated in rtTA-
psRANKL transgenic and wild type pig.  
To test the effect of Doxy dose on transgene expression in vivo, rtTA-psRANKL transgenic 
boar 9961 was treated with ascending doses of Doxy (6.3, 12.5, 25, and 50 mg/kg body 
weight per day for 10 days each), resulting in a more or less dose-dependent increase in 
plasma RANKL concentrations. This observation demonstrates the achievement of a tightly 
controlled Tet-On system in transgenic pigs. Additionally, RANKL upregulation has been 
proven in osteoporotic women [253] and the OPG-/- mice, which exhibit an aberrant bone 
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metabolism, characterized by accelerated bone resorption [104,105,254]. Because the serum 
concentration of RANKL is markedly elevated in these mice [255], the circulating RANKL 
may be directly involved in osteoclastogenesis. 
Biochemical markers of resorption and formation that provide sensitive and dynamic indices 
of bone turnover may be a useful investigation tool for quantifying and monitoring the effects 
of anti-osteoporotic drugs [253]. Recent data suggest that some molecular markers could 
provide a more profound analysis of the changes of resorption and show parallel changes of 
osteoclast function and number. These markers include osteoclast specific enzymes, tartrate-
resistant acid phosphatase 5b (TRACP5b) and Cathepsin K [256,257], which may reflect the 
number of osteoclast and the Cathepsin K generated degradation fragments of collagen type I 
(NTX and CTX), which reflect the function of the osteoclasts [258]. Recently, Meier et al. 
[259] conclude that serum Cathepsin K appeared to discriminate better between osteoporotic 
and non-osteoporotic women compared with other bone turnover marker like ALP. For these 
reasons, we have chosen Cathepsin K and CTX as a means of showing osteoporotic 
phenotype. Additionally, circadian rhythms are known to exist for bone turnover and bone 
mineral metabolism, thus the time point of the collection of the samples may be very relevant 
for interpretation of the results [260-265]. 
In transgenic pig an obvious difference of plasma Cathepsin K levels was detected, comparing 
a non-transgenic littermate control at day 10 for 0,5X doses and at day 3 for 1X doses. At 
those time points, it can be stated that transgenic pig does develop an induced osteoporotic 
phenotype. The discrepancy in the expression pattern is probably due to different time points 
of collection of the samples. 
No significant differences in serum CTX levels could be determined in transgenic pig when 
compared to its non-transgenic littermate control animal at any time point investigated. The 
C-telopeptide fragments of type I collagen measured in the CrossLaps ELISA that we used, 
was generated in bone; however, it may also be generated by several tissues unrelated to bone, 
because of the widespread occurrence of type I collagen in the body [266], thus masking the 
obtained results. Furthermore, the altered temporal relationship of the CTX may reflect 
changes in the indirect effect of RANKL.  
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5. CONCLUSIONS 
 
1. Newly cloned porcine sRANKL cDNA has a template of 842 bps and a protein of 280 
amino acids with molecular weight of 31,7 kDa with predicted pI of 6,90. 
 
2. Porcine and human sRANKL share high sequence homology. 
 
3. Sequence analysis suggests that TNF domain is located at C-terminus of porcine 
sRANKL. 
 
4. Lentiviral gene transfer successfully over-expressed porcine sRANKL at a high level 
and in soluble form from porcine fibroblasts. 
 
5. Porcine osteoclasts can be generated by human sRANKL, showing typical osteoclastic 
morphology. 
 
6. Porcine sRANKL can stimulate osteoclastogenesis in vitro. 
 
7. Porcine sRANKL is inducible in cells after Doxycycline stimulation in a Tet-On 
system. 
 
8. Double-transgenic fetuses generated by electroporation of the lentiviral construct 
express rtTA and induce low porcine sRANKL upon Doxycycline stimulation in ear 
fibroblasts. 
 
9. rtTA-psRANKL piglets originated from double-transgenic fetus 3 were born dead and 
their cells do not induce porcine sRANKL. 
 
10. rtTA-transgenic piglets express rtTA at high level. 
 
11. Electroporation of rtTA-kidney cells with TRE-psRANKL vector showed the 
induction of porcine sRANKL upon Doxycycline stimulation. 
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12. The rtTA-kidney cells electroporated with TRE-psRANKL vector from piglet 9894 
showed the best expressional and inductional pattern. 
 
13. The rtTA-psRANKL cells from piglet 9894 were used for further re-cloning of 
transgenic animals. 
 
14. Re-cloned rtTA-psRANKL transgenic piglets are expressing rtTA, but don’t induce 
psRANKL upon stimulation in ear fibroblasts. 
 
15. rtTA-psRANKL transgenic pig shows upregulation of resorption markers in blood. 
 
16. rtTA-psRANKL transgenic pig shows induction of RANKL in plasma upon 
Doxycycline stimulation. 
 
In conclusion, our results strongly suggested that extracellular domain of newly cloned 
porcine RANKL is able to mediate osteoclast formation and function. Moreover, until now 
there are no published data about a transgenic pig carrying the rtTA inducible gene expression 
system (Tet-On system). In mice several transgenic models with tetracycline-controllable 
gene expression were already established [210,267,268]. Therefore, we produced the first 
piglet that exhibited functional Tet-On and showed inducible expression of the desired gene. 
Future analysis will show what impact has a long time over-expression of psRANKL on 
piglet 9961. We can only assume that this piglet will develop an osteoporotic phenotype. 
Moreover, in 7-8 month old mice, over-expression of sRANKL led to a significant 
deprivation of the femur bone mineral density, due to promoted osteoclast formation [105]. 
Thus, our transgenic pig would be useful tool as a therapeutic model and for the clarification 
of further physiological and pathological functions of sRANKL in vivo. 
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6. SUMMARY 
 
Introduction: Osteoporosis, a bone disease which is characterized by a reduction of bone 
mass, affects many people worldwide. RANKL (Receptor Activator of NF-κB Ligand) is a 
cytokine belonging to the TNF superfamily and is essential for osteoclast differentiation. 
During normal bone turnover RANKL stimulates the formation and activity of osteoclasts, by 
binding to its receptor RANK, which expressed on osteoclasts and their progenitors. These 
processes are disrupted by binding of RANKL to osteoprotegerin (OPG), a soluble decoy 
receptor. Unfortunately, many mouse disease models often do not faithfully mimic the 
relevant human conditions. Therefore, the swine has been used as a major mammalian model 
for human biology. The similarity in size, physiology, organ development and disease 
progression make the swine an ideal model. The aim of this study was to over-express 
sRANKL in order to obtain an osteoporotic large animal model. Thus, we designed a 
construct encoding the tetracycline transactivator under constitutive promoter and 
extracellular domain of porcine RANKL under tetracycline-regulated promoter using so 
called Tet-On system. Finally, the transgenic piglets were obtained.  
 
Materials and methods: A lentiviral transfer of psRANKL cDNA into porcine cells was 
applied for over-expression of the psRANKL protein. Quantitative PCR, Western blot and 
immunocitochemistry were used to assess the over-expression. Giemsa, TRACP, Phalloidin 
and Concanavalin A stainings were used to characterize generated porcine osteoclasts. 
Calcifluor assay was used to estimate the extent of osteoclast resorption. Somatic cell nuclear 
transfer was used to generate transgenic animals. Genomic PCR, RT-PCR, Western blot and 
ELISAs were used to evaluate the expression pattern of the transgenic animals. 
 
Results: The development of the first large animal model for osteoporosis is described in this 
thesis. To obtain this, porcine sRANKL was first cloned. Sequence analysis and functional 
characterization of the newly cloned porcine sRANKL suggested that the TNF-like core 
domain is essential for the induction of osteoclastogenesis. For gaining a controllable 
expression of porcine sRANKL, it was necessary to establish a Tet-On system to sidestep 
harmful effects of RANKL over-expression during the fetal development. The first attempt to 
integrate both genes, transactivator (rtTA) and psRANKL, in a single step of cell transfection 
was successful, i.e. the cells induced psRANKL after Doxycycline stimulation. Unfortunately, 
after nuclear transfer of the cells having the same construct, the expression analysis produced 
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no satisfying result. We obtained two transgenic fetuses, showing an expression of rtTA and 
low inducibility of porcine sRANKL. Therefore, the strategy was changed in favor to two 
rounds of transfection and nuclear transfer. First rtTA-transgenic piglets were established and 
screened for integration and expression. One of five rtTA-piglets (piglet 9894) showed the 
best expression and severed as donor for next cell transfection step. These rtTA-psRANKL 
cells were tested in vitro for their inducibility. After this the nuclear transfer and embryo 
transfer of the best candidate was performed and it resulted in 4 pregnancies which all 
finished to term. The only alive double transgenic piglet (9961) was raised and will be kept 
until adulthood to establish a founder line of rtTA-psRANKL transgenic pigs, as well as for 
first studies on inducibility of psRANKL over-expression. Stimulation of this pig with 
Doxycycline resulted in increased serum levels of porcine sRANKL. Furthermore, elevated 
psRANKL levels caused an increase in bone resorption markers. Serum levels of Cathepsin K 
were significantly upregulated, strongly suggesting that the newly cloned porcine sRANKL is 
also functionally active in vivo.  
 
Conclusions: Cloning and sequencing of the extracellular domain of the porcine homologue 
of RANKL showed that it has a high similarity with human sRANKL. The porcine 
homologue has an important role in regulation of bone homeostasis and osteoclastic function. 
These findings show for the first time that porcine sRANKL is sufficient to induce osteoclasts 
in vitro. In addition, many physiological characteristics of the pigs are more similar to the 
humans than those of the mouse. Moreover, the large size of a pig model facilitates a plethora 
of physiological and molecular studies as well as therapeutic trials that cannot be performed 
in the small rodent models. Thus, the sRANKL
 
transgenic pig is a novel animal model with 
clinical relevance for osteoporosis research and treatment. Furthermore, other constructs 
might be based on the existing Tet-On system, offering an inducible system for a broad 
variety of different transgenes. In addition the present work describes a functional Tet-On 
system in pigs for the first time. 
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7. ZUSAMMENFASSUNG 
 
Einleitung:  Osteoporose, eine Knochenkrankheit bei der sich die Knochendichte verringert, 
betrifft weltweit viele Menschen. RANKL (Rezeptor Aktivator des NF-κB Liganden), ein 
Zytokin, gehört zur TNF-Superfamilie und ist essentiell für die Differenzierung der 
Osteoklasten. Während des normalen Knochenumbaus stimuliert RANKL die Bildung und 
Aktivität von Osteoklasten indem es an seinen Rezeptor RANK bindet, welcher auf 
Osteoklasten und ihren Verläuferzellen exprimiert wird. Gestört werden diese Prozesse durch 
die Bindung von RANKL an Osteoprotegerin (OPG), einem löslichen Rezeptor. Mausmodelle 
spiegeln die relevanten menschlichen Bedingungen für Osteoporose nur unzureichend wieder. 
Aus diesem Grund ist das Schwein ein wichtiges Tiermodell für die Untersuchung der 
menschlichen Biologie, da die Ähnlichkeiten in der Größe, der Physiologie, der 
Organentwicklung und des Krankheitsverlaufs das Schwein zu einem idealen Säugetiermodell 
machen. Das Ziel dieser Studie war die regulierte Überexpression des sRANKL, um ein 
Großtiermodell zu erstellen. Deshalb haben wir ein Konstrukt entwickelt, welches über einen 
Tetracyclin-regulierten Promotor (sog. Tet-On System) den Tetracyclin-Transaktivator bindet. 
In diesem Komplex befinden sich außerdem ein konstruktiver Promotor und eine 
extrazelluläre Domäne des Schweine RANKL. Sclussendlich konnten transgenetische 
Schweine entwickelt werden.  
 
Materialen und Methoden: Mit Hilfe des lentiviralen Gentransfers wurde die psRANKL-
cDNA in Schweinezellen eingebracht, um eine Überexpression des psRANKL Proteins zu 
erreichen. Zur Überprüfung der Überexpression wurden verschiedene Verfahren wie 
quantitative PCR, Western Blot und Immunzytochemie verwendet. Speziell zur 
Charakterisierung der Schweine Osteoklasten wurden Giemsa, TRACP, Phalloidin und 
Concanavalin A Färbungen durchgeführt. Durch die Anwendung des Calcifluor Assays wurde 
der Osteoklastenabbau dokumentiert. Für die Generierung der transgenen Tiere wurde der 
Kerntransfer angewendet. Zur Überprüfung des Expressionsmusters der transgenen Tiere 
wurden verschiedene Methoden wie Southern Blot, RT-PCR, Western Blot und ELISA 
durchgeführt. 
 
Ergebnisse: In dieser Arbeit wird die Erstellung des ersten genetischen Großtiermodells  zur 
Untersuchung der Osteoporose beschrieben. Dafür wurde das porcine sRANKL von uns 
erstmals kloniert. Sequenzanalysen und die Funktionscharakterisierung des neu geklonten 
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psRANKL wiesen daraufhin, dass die TNF-ähnliche Kerndomäne eine wesentliche Rolle für 
die Induktion der Osteoklastogenese spielt. Um eine kontrollierbare Expression des 
psRANKL zu erreichen, war es notwendig ein Tet-On System zu etablieren, um 
gesundheitsschädlichen Nebenwirkungen in der Embryonalentwicklung zu vermeiden. Der 
Versuch beide Gene, Transaktivator (rtTA) und psRANKL, in einem einzigen 
Transfektionsschritt zu integrieren war im ersten Anlauf erfolgreich, d. h. die Zellen 
produzierten nach Stimulation mit Doxycyclin psRANKL. Jedoch ergab eine 
Expressionsanalyse von Zellen mit dem gleichen Konstrukt nach einem Kerntransfer keine 
zufriedenstellenden Ergebnisse. Wir erhielten drei transgene Feten mit rtTA Expression und 
allerdings niedriger sRANKL Induzierbarkeit. Deshalb wurden darufhin zwei 
Transfektionsschritte und zwei Kerntransfers durchgeführt. Nach der Geburt der ersten rtTA-
transgenen Ferkel wurden diese auf die Genintegration und –expression überprüft. Es wurde 
ein von fünf rtTA-Ferkeln (Ferkel 9894) identfiziert, welches die beste Expression zeigte. 
Dieses Tier wurde als Donor für den nächsten Kern- und Embryotransfer verwendet. Zunächst 
wurden die rtTA-psRANKL Zellen in vitro auf ihre Induzierbarkeit getestet. Danach wurde 
der Kern- und Embryotransfer des besten Kandidaten durchgeführt, welches in 4 
Schwangerschaften resultierte, die alle ausgetragen wurden. Das einzige lebende doppelt 
transgene Ferkel (9961) wurde aufgezogen, um eine Gründerlinie von rtTA-psRANKL 
transgenen Schweinen zu etablieren. Des Weiteren wurde die Induzierbarkeit von psRANKL 
Überexpression untersucht. Die Stimulierung dieses Schweins mit Doxycyklin resultierte in 
einem erhöhten Serumspiegel von psRANKL. Weiterhin sorgt der angestiegene psRANKL 
Spiegel für eine Erhöhung der Knochenresorptionsmarker. Die Werte von Cathepsin K und 
CTX waren signifikant erhöht, woraus geschlossen werden kann, dass das neu klonierte 
psRANKL auch in vivo funktionell ist. 
 
Schlussfolgerung: Die Klonierung und die Sequenzierung der extrazellulären Domäne des 
Schweine RANKL zeigt eine große Ähnlichkeit mit dem humanen RANKL. Das 
Schweinehomolog spielt eine große Rolle in der Knochenhomeostase und der 
Osteoklastenfunktion. Diese Ergebnisse zeigen zum ersten Mal, das auch Schweine sRANKL 
in der Lage ist Osteoklasten in vitro zu induzieren. Darüber hinaus eröffnen diese 
Erkenntnisse die Möglichkeit für physiologische und molekularbiologische Studien, als auch 
therapeutische Untersuchungen, welche nicht im Nagerkleintiermodell durchgeführt werden 
können. Aus diesem Grund ist das sRANKL transgene Schwein ein neues, klinisch relevantes 
Tiermodell für die Osteoporose-Forschung und Behandlung. Zudem eröffnet das Tet-ON-
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transgene Schwein die Möglichkeit andere regulierte Modelle mit unterschiedlichen 
Transgenen zu generieren. In der vorliegenden Studie wird außerdem das funktionierende 
Tet-On System im Schwein zu ersten Mal beschrieben. 
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1,23(OH)2D3 1,23-dihydroxyvitmain D3 
100 kbp M 100 kbp marker 
293FT cells Human embryonal kidney cell line (HEK) 
ALP Alkaline phosphatase 
AMV Avian Myeloblastosis Virus 
BCA Bicinchoninic acid 
BGH Bovine growth hormone 
Bla Blasticidin  
BM Bone marrow 
BMD Bone mineral density 
BMU Basic multicellular unit 
bp Base pair 
BSA Bovine serum albumin 
BSP Bone sialoprotein 
C1NP C-terminal type 1 procollagen 
CAG Chicken β-actin 
CA-II Carbonic anhydrase type II 
CD59 Protectin 
cDNA Complemetary DNA 
c-Fms Colony stimulating factor 1 receptor 
CMV Cytomegalovirus 
c-myc V-myc myelocytomatosis viral oncogene homolog 
CT Calcitonin 
CTX Collagen type 1 cross-linked C-telopeptide 
DAB Diaminiobenzidene 
DAF Decay-accelerating factor 
DAP12 DNAX-activating protein 12 
DAPI 4,6-diamidino-2-phenylindole 
DAR DAP12-associated receptor 
DEXA Dual energy X-ray absorptiometry 
DFG Deutsche Forschungsgemeinschaft 
D-MEM Dulbeco's minimal esential media 
DMSO Dimethylsulfoxid 
DNA Deoxyribonucleic acid 
DNase Desoxyribonuklease 
dNTP Deoxyribonucleotide triphosphate 
Doxy Doxycycline  
DPD Deoxypyridinoline  
DTT Dithiothreitol 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme linked immunosorbent assay 
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ET Embryo transfer 
F-actin Filamentous actin 
FBS Fetal bovine serum 
FcRγ Fc receprot common γ subunit 
FDA Federal drug administration 
FSD Functional secretory domain 
g Gravitational force 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
Gbp Giga base pair 
GFP Green fluorescent protein 
HIV-I Human immunodeficiency virus type I 
HMSC Human mesenchymal stem cells 
hRANKL Human RANKL 
HSC Hematopoietic stem cells 
hsRANKL Human soluble RANKL 
ICSI Intracytoplasmic sperm injection 
IFNγ Interferon gamma 
Ig Immunoglobulin 
IGF-I Insulin-like growth factor 
IGFR Insulin growth factors receptor 
IL-1, 11 Interleukin 1, 11 
IU International unit 
JNK c-jun N-terminal kinase 
KLF4 Krueppel-like Factor 4 
LB Luria Bertani 
LTR Long terminal repeats 
M-CSF Macrophage colony stimulating factor 
MGP Matrix Gla protein 
min Minute 
mRNA Messenger RNA 
MSC Mesenchymal stromal cells or mesenchymal stem cells 
NCP Non-collagenous protein 
NEAA Non essential amino acids 
Neo Neomycin 
NF-κB Nuclear factor κ of activated B-cells 
NT Nuclear transfer 
NTX Collagen type 1 cross-linked N-telopeptide 
OCT4 Octamer binding transcription factor 4 
ODF Osteoclast Differentiation Factor 
OPG Osteoprotegerin  
OPGL Osteoprotegerin ligand 
Opti-MEM Modified eagle’s minimum essential media 
OSCAR Osteoclast-associated receptor 
P1NP N-terminal type 1 procollagen 
PBS Phosphate buffered saline 
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pDNA Plasmid DNA 
pEF Porcine ear fibroblast 
Pen-Strep Penicillin-streptomycin 
PFA Paraformaldehyde 
pFF Porcine fetal fibroblast 
PGE2 Prostaglandin 2 
PI Propidium iodide 
PI(3)K Phosphoinositide 3-kinases 
PIR-A Paired immunoglobulin-like receptor A 
pKC Porcine kidney cell 
pRANKL Porcine RANKL 
psRANKL Porcine solube RANKL 
PTH Parathyroid hormone 
pUC Plasmid cloning vector 
PVDF Polyvinylidene Fluoride 
PYD Pyridinoline  
RANK Receptor activator of NF-κB 
RANKL Receptor activator of NF-κB ligand 
RB Ruffled border 
RNA Ribonucleic acid 
RNase Ribonucleic acid nuclease 
rpm Round per minute 
RT Room temperature 
RT-PCR Reverse transcriptase polymerase chain reaction 
rtTA Reverse Tetracycline-responsive transactivator 
S.O.C Super optimal broth with Catabolite repression 
SCNT Somatic cell nuclear transfer 
SDS Sodium dodecyl sulfate 
shRANKL Soluble human RANKL 
SOX2 Sex determining region Y box 2 
sRANKL Soluble RANKL 
Stbl3 Competent E. coli strain 
SV40 Simian virus 40 
TACE TNFα converting enzyme 
Tc Tetracycline 
Tet system Tetracycline system 
TetR Tet repressor 
TGF Transforming growth factor 
THD TNF homology domain 
TNF Tumor necrosis factor 
TNFR Tumor necrosis factor receptor 
TNFα Tumor necrosis factor α 
TRAF2,5,6 TNF receptor-associated factor 2, 5, 6 
TRANCE TNF-related activation-induced cytokine 
TRACP Tartrate resistant acid phosphatase 
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TRACP5b Tartrate-resistant acid phosphatase 5b 
TRE Tetracycline response element 
tTA Tetracycline-responsive transactivator 
U Unit 
V-ATPase Vacuolar-type H+-Adenosintriphosphatase 
VP16 Etoposide phosphate 16 
WHO World health organization 
WT Wild type 
αMEM Eagle’s minimum essential medium 
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APPENDIX 
 
Supplementary tables 
 
Supplementary table 1.: Nucleotide sequences of the primer sets used in this study. 
Target 
gene 
 
Sequence 
PCR conditions (annealing 
temperature, cycle number) and band 
size 
F 5´-GCACATCAGAGCAGAGAAAG-3´ 
sRANKL 
R 5´-TTTCCTCTCCAGACCGTAAC-3´ 
55°C, 30x 
F 5´-GAAAGTGGGTCCGCGTACAG-3´ 
rtTA 
R 5´-ATATCCAGAGCGCCGTAGGG-3´ 
55°C, 30x, 335 bps 
F 5´-CACTCCTGCTATGGGTACTG-3´ 
psRANKL 
R 5´-AACCGGATGGGATGTCTGTG-3´ 
55°C, 30x, 411 bps 
F 5´-TCAACAACGGCCACTCTTTC-3 
CA-II 
R 5´-TGTGCAGCTTCTCCAAAGTC-3´ 
57°C, 26x, 225 bps 
F 5´-CAACTACATGGTTTACATGTTC-3´ 
GAPDH 
R 5´-GCCAGTGGACTCCACGAC-3´ 
55°C, 30x, 177 bps 
* F- forward, R- reverse 
 
 
Supplementary table 2.: List of primary and secondary antibodies used in this study. 
Name Manufacturer Host, affinity Application Dilutions 
Primary antibodies 
Anti-Tet-repressor Mobitec Mouse, polyclonal ICH 1: 50 
TetR Clontech Mouse, polyclonal WB 1: 500 
Anti human sRANK Ligand PeproTech Rabbit, polyclonal WB and ICH 1: 500 and 1:50 
Secondary antibodies 
Anti- mouse AF488 Invitrogen Donkey ICH 1: 200 
Anti-mouse biotynilated Vector Labs Goat, polyclonal ICH 1:200 
Anti-mouse HRP Rockland Rabbit WB 1: 4000 
Anti-rabbit HRP Santa Cruz Goat WB 1: 4000 
Anti-rabbit biotynilated Vector Labs Goat, polyclonal ICH 1:200 
Anti-rabbit AF488 Invitrogen Goat ICH 1: 500 
Phalloidin Invitrogen  ICH 1:20 
Concanavalin A Invitrogen  ICH 24 µg/ml 
* WB – Western blotting, ICH - immunocitochemistry 
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Supplementary figures 
 
Supplementary figure 1.: Cells used in this study. A) 293FT; B) Porcine fetal fibroblast (pFF); C) Porcine ear 
fibroblast (pEF); D) Porcine kidney cells (pKC); E) Porcine osteoclast precursor cells. 
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Supplementary figure 2.: Graphical representation of commercially available plasmid used in this study. A) 
pCR2.1-TOPO; B) pSecTag2ABC; C) pENTR11; D) pLenti6/V5-DEST; E) pTet-On; F) pTRE-Tight. 
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Supplementary figure 3.: Graphical representation of pENTR11-psRANKL plasmid.  
 
 
Supplementary figure 4.: Graphical representation of pLenti6/V5-psRANKL. 
 
 
Supplementary figure 5.: Graphical representation of rtTA-psRANKL (Neo) plasmid. 
 
 
Supplementary figure 6.: Graphical representation of CAG-rtTA plasmid. 
 
 
Supplementary figure 7.: Graphical representation of TRE-psRANKL plasmid. 
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